<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22970105</article-id><article-id pub-id-type="pmc">3433792</article-id><article-id pub-id-type="publisher-id">PONE-D-12-11386</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0043803</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Genetics</subject><subj-group><subject>Human Genetics</subject><subj-group><subject>Genetic Association Studies</subject><subject>Mitochondrial Diseases</subject></subj-group></subj-group><subj-group><subject>Population Genetics</subject><subj-group><subject>Haplotypes</subject></subj-group></subj-group><subj-group><subject>Genetics of Disease</subject></subj-group></subj-group><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group><subj-group><subject>Genetics of the Immune System</subject></subj-group></subj-group><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Antivirals</subject></subj-group></subj-group></subj-group><subj-group><subject>Population Biology</subject><subj-group><subject>Population Genetics</subject><subj-group><subject>Haplotypes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Genetics</subject><subj-group><subject>Mitochondrial Diseases</subject></subj-group></subj-group><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group><subj-group><subject>Immunity</subject><subj-group><subject>Immune Activation</subject></subj-group></subj-group><subj-group><subject>Genetics of the Immune System</subject></subj-group></subj-group><subj-group><subject>Infectious diseases</subject><subj-group><subject>Sexually Transmitted Diseases</subject><subj-group><subject>AIDS</subject></subj-group></subj-group><subj-group><subject>Viral diseases</subject><subj-group><subject>HIV</subject><subj-group><subject>Retrovirology and HIV immunopathogenesis</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>T Cell Activation Markers and African Mitochondrial DNA Haplogroups
among Non-Hispanic Black Participants in AIDS Clinical Trials Group Study
384</article-title><alt-title alt-title-type="running-head">mtDNA Variation and T Cell Activation in
HIV</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hulgan</surname><given-names>Todd</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Robbins</surname><given-names>Gregory K.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kalams</surname><given-names>Spyros A.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Samuels</surname><given-names>David C.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Grady</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Shafer</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Murdock</surname><given-names>Deborah G.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Selph</surname><given-names>Doug</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Haas</surname><given-names>David W.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pollard</surname><given-names>Richard B.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><on-behalf-of>for the AIDS Clinical Trials Group</on-behalf-of></contrib><contrib contrib-type="author"><collab>AIDS Clinical Trials Group<contrib-group><contrib contrib-type="author"><name><surname>De Gruttola</surname><given-names>Victor</given-names></name><aff>Harvard School of Public Health</aff></contrib><contrib contrib-type="author"><name><surname>Snyder</surname><given-names>Sally</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nevin</surname><given-names>Thomas</given-names></name><aff>Social &#x00026; Scientific Systems</aff></contrib><contrib contrib-type="author"><name><surname>Pettinelli</surname><given-names>Carla</given-names></name><aff>National Institutes of Health</aff></contrib><contrib contrib-type="author"><name><surname>Dube</surname><given-names>Michael</given-names></name><aff>Indiana University</aff></contrib><contrib contrib-type="author"><name><surname>Fischl</surname><given-names>Margaret</given-names></name><aff>Miami University</aff></contrib><contrib contrib-type="author"><name><surname>Delaphna</surname><given-names>Robert</given-names></name><aff>Howard University</aff></contrib><contrib contrib-type="author"><name><surname>Gideon</surname><given-names>Linda</given-names></name><aff>Frontier Science and Technology Foundation</aff></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Aquila</surname><given-names>Richard</given-names></name><aff>Vanderbilt University</aff></contrib><contrib contrib-type="author"><name><surname>Vella</surname><given-names>Stefano</given-names></name><aff>Istituto Superiore de Sanita</aff></contrib><contrib contrib-type="author"><name><surname>Merigan</surname><given-names>Thomas</given-names></name><aff>Stanford University</aff></contrib><contrib contrib-type="author"><name><surname>Hirsch</surname><given-names>Martin</given-names></name><aff>Harvard Medical School</aff></contrib></contrib-group></collab><xref ref-type="author-notes" rid="fn1">
<sup>&#x000b6;</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Vanderbilt University School of Medicine,
Nashville, Tennessee, United States of America</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Massachusetts General Hospital/Harvard
University, Boston, Massachusetts, United States of America</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Stanford University Medical Center, Stanford,
California, United States of America</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>University of California Davis, Sacramento,
California, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Unutmaz</surname><given-names>Derya</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>New York University, United States of
America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>todd.hulgan@vanderbilt.edu</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have read the journal&#x02019;s policy and have the following
conflicts: TH has received research support from Merck. GKR has received
research support from Gilead Sciences, Schering-Plough. DWH has received
research grants from Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead
Sciences, and Merck, and has served as a consultant for
Boehringer-Ingelheim. AIDS Clinical Trials Group (ACTG) Study 384 was also
supported in part by Agouron/Pfizer, Bristol Myers Squibb, and
GlaxoSmithKline. This does not alter the authors&#x02019; adherence to all the
PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: TH GKR SAK DCS RS DGM DWH RBP.
Performed the experiments: GKR DCS BG RS DS RBP. Analyzed the data: TH DCS
BG DS. Contributed reagents/materials/analysis tools: TH DCS BG DS. Wrote
the paper: TH GKR DCS RBP. Critically revised the manuscript: TH GKR SAK DCS
BG RS DGM DS DWH RBP. Approved the final version to be published: TH GKR SAK
DCS BG RS DGM DS DWH RBP.</p></fn><fn id="fn1" fn-type="other"><p>&#x000b6; Membership of the AIDS Clinical Trials Group is provided in the
Acknowledgments.</p></fn></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2012</year></pub-date><volume>7</volume><issue>8</issue><elocation-id>e43803</elocation-id><history><date date-type="received"><day>30</day><month>3</month><year>2012</year></date><date date-type="accepted"><day>26</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; 2012 Hulgan et al</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Hulgan et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Mitochondrial function influences T cell dynamics and is affected by
mitochondrial DNA (mtDNA) variation. We previously reported an association
between African mtDNA haplogroup L2 and less robust CD4 cell recovery on
antiretroviral therapy (ART) in non-Hispanic black ACTG 384 subjects. We
explored whether additional T cell parameters in this cohort differed by
mtDNA haplogroup.</p></sec><sec><title>Methods</title><p>ACTG 384 randomized ART-na&#x000ef;ve subjects to two different nucleoside
regimens with efavirenz, nelfinavir, or both. CD4 and CD8 memory and
activation markers were available at baseline and week 48 on most subjects.
mtDNA sequencing was performed on whole blood DNA, and haplogroups were
determined. We studied non-Hispanic black subjects with HIV RNA &#x0003c;400
copies/mL at week 48. Analyses included Wilcoxon ranksum test and linear
regression.</p></sec><sec><title>Results</title><p>Data from 104 subjects were included. Major African mtDNA haplogroups
included L1 (N&#x0200a;=&#x0200a;25), L2 (N&#x0200a;=&#x0200a;31),
and L3 (N&#x0200a;=&#x0200a;32). Baseline age, HIV RNA, and CD4 cells
did not differ between L2 and non-L2 haplogroups. Compared to non-L2
haplogroups, L2 subjects had lower baseline activated CD4 cells (median
12% vs. 17%; p&#x0200a;=&#x0200a;0.03) and tended toward
lower activated CD8 cells (41% vs. 47%;
p&#x0200a;=&#x0200a;0.06). At 48 weeks of ART, L2 subjects had smaller
decreases in activated CD4 cells (&#x02212;4% vs. &#x02212;11%;
p&#x0200a;=&#x0200a;0.01), and smaller CD4 cell increases (+95 vs.
+178; p&#x0200a;=&#x0200a;0.002). In models adjusting for baseline
age, CD4 cells, HIV RNA, and na&#x000ef;ve-to-memory CD4 cell ratio, haplogroup
L2 was associated with lower baseline (p&#x0200a;=&#x0200a;0.04) and
48-week change in (p&#x0200a;=&#x0200a;0.01) activated CD4 cells.</p></sec><sec><title>Conclusions</title><p>Among ART-na&#x000ef;ve non-Hispanic blacks, mtDNA haplogroup L2 was associated
with baseline and 48-week change in T cell activation, and poorer CD4 cell
recovery. These data suggest mtDNA variation may influence CD4 T cell
dynamics by modulating T cell activation. Further study is needed to
replicate these associations and identify mechanisms.</p></sec></abstract><funding-group><funding-statement>Funding for the genomic sequencing was provided by the National
Institutes of Health (NIH)/National Institute of Neurological Diseases and
Stroke grant NS059330. The project described was also supported by Award Number
U01AI068636 from the National Institute of Allergy and Infectious Diseases and
supported by National Institute of Mental Health (NIMH), and National Institute
of Dental and Craniofacial Research (NIDCR). AIDS Clinical Trials Group (ACTG)
Study 384 was also supported by grant AI38858, and by Agouron/Pfizer, Bristol
Myers Squibb, and GlaxoSmithKline. The ACTG sites contributing DNA for these
analyses were funded by NIH grants AI069513, AI34835, AI069432, AI069423,
AI069477, AI069501, AI069474, AI069428, AI69467, AI069415, Al32782, AI27661,
AI25859, AI069495, AI069471, AI069532, AI069452, AI069450, AI069556, AI069484,
AI069472, AI34853, AI069465, AI069511, AI38844, AI069424, AI069434, AI46370,
AI069502, and AI069419. The ACTG Human DNA Repository is also supported in part
by the National Center for Advancing Translational Sciences of the National
Institutes of Health under Award Number UL1 TR000445. Additional NIH grant
support included: AI077505, AI54999, HL087726, AI69495, 5T32GM80178 and
AI062435. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of Allergy
and Infectious Diseases or the National Institutes of Health. The funders had no
role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The CD4<sup>+</sup> T-lymphocyte is the primary cellular target of HIV, and the
absolute CD4<sup>+</sup> T lymphocyte count is a reliable determinant of
disease progression and opportunistic infection risk among HIV-infected persons. The
CD4 count is also a major factor in the decision to initiate antiretroviral therapy
(ART) in asymptomatic HIV-infected individuals <xref rid="pone.0043803-Kitahata1" ref-type="bibr">[1]</xref>. After initiating ART, there
is substantial interindividual variability in the rate and magnitude of CD4 recovery
<xref rid="pone.0043803-Gutierrez1" ref-type="bibr">[2]</xref>. Many
ART-treated patients (as many as 30%) fail to attain substantial increases in
CD4 count <xref rid="pone.0043803-Gutierrez1" ref-type="bibr">[2]</xref>&#x02013;<xref rid="pone.0043803-Gazzola1" ref-type="bibr">[3]</xref>, and poorer CD4 count responses on ART are associated with
disease progression despite adequate virologic responses <xref rid="pone.0043803-Gutierrez1" ref-type="bibr">[2]</xref>, <xref rid="pone.0043803-Grabar1" ref-type="bibr">[4]</xref>. Host genetic variation appears
to play a role in CD4 count recovery. Studies have suggested possible associations
between CD4 count recovery on ART and single nucleotide polymorphisms (SNPs) in
chemokine receptor <xref rid="pone.0043803-Rigato1" ref-type="bibr">[5]</xref>&#x02013;<xref rid="pone.0043803-Ahuja1" ref-type="bibr">[6]</xref>, human leukocyte antigen <xref rid="pone.0043803-Rauch1" ref-type="bibr">[7]</xref>&#x02013;<xref rid="pone.0043803-Soria1" ref-type="bibr">[8]</xref>, cytokine <xref rid="pone.0043803-Haas1" ref-type="bibr">[9]</xref>, and apoptosis-related <xref rid="pone.0043803-Nasi1" ref-type="bibr">[10]</xref> genes. These
results highlight the possibility that an important host factor that influences
HIV-infected CD4 cell turnover is regulation of apoptosis <xref rid="pone.0043803-Varbanov1" ref-type="bibr">[11]</xref>&#x02013;<xref rid="pone.0043803-Petit1" ref-type="bibr">[12]</xref>.</p><p>T cell activation is a highly energy-dependent process that is a hallmark of chronic
HIV-1 infection and is a predictor of CD4 T cell recovery on ART <xref rid="pone.0043803-Hunt1" ref-type="bibr">[13]</xref>&#x02013;<xref rid="pone.0043803-Gandhi1" ref-type="bibr">[17]</xref>. T cell
activation is associated with cellular apoptosis <xref rid="pone.0043803-Gougeon1" ref-type="bibr">[18]</xref>&#x02013;<xref rid="pone.0043803-Gougeon2" ref-type="bibr">[20]</xref> and can be attenuated with
ART, but not completely or to the same degree in all persons <xref rid="pone.0043803-Nakanjako1" ref-type="bibr">[21]</xref>&#x02013;<xref rid="pone.0043803-Robbins1" ref-type="bibr">[22]</xref>. Given that mitochondria play
critical roles in energy production, oxidative stress, and apoptosis, their
importance in cellular immune responses and T cell turnover seems apparent. Indeed,
the importance of mitochondria-mediated, intrinsic apoptotic pathways in normal T
cell homeostasis <xref rid="pone.0043803-Bouillet1" ref-type="bibr">[23]</xref>&#x02013;<xref rid="pone.0043803-Grimaldi1" ref-type="bibr">[24]</xref>, and in dysregulated CD4 T cell recovery during HIV-1
infection <xref rid="pone.0043803-Negredo1" ref-type="bibr">[25]</xref>
have been described. Other investigations have identified associations between T
cell activation and apoptosis that influence CD4 T cell depletion during HIV-1
infection and are improved by ART <xref rid="pone.0043803-Badley1" ref-type="bibr">[26]</xref>&#x02013;<xref rid="pone.0043803-Johnson1" ref-type="bibr">[28]</xref>.</p><p>Within mtDNA, combinations of SNPs allow for categorization of individuals into
haplogroups <xref rid="pone.0043803-Wallace1" ref-type="bibr">[29]</xref>.
Haplogroups and other mtDNA variants have been associated with differences in
mitochondrial function <xref rid="pone.0043803-GomezDuran1" ref-type="bibr">[30]</xref>&#x02013;<xref rid="pone.0043803-Brown1" ref-type="bibr">[31]</xref>, and the clinical relevance of haplogroups- and mtDNA
variation in general- for disease risk is well described <xref rid="pone.0043803-DeBenedictis1" ref-type="bibr">[32]</xref>&#x02013;<xref rid="pone.0043803-Raule1" ref-type="bibr">[35]</xref>, Few studies
have examined mitochondrial DNA (mtDNA) in T cell subsets in HIV-1-infected subjects
in the absence of ART toxicity. One described decreased mtDNA quantity in activated
(CD8&#x0003e;CD4) T cells compared with non-activated subsets from HIV-1 seroconverters
<xref rid="pone.0043803-Casula1" ref-type="bibr">[36]</xref>. In
another recent study, loss of mtDNA that correlated with activation was seen in CD8
T cells of HIV-1-infected, ART-na&#x000ef;ve subjects <xref rid="pone.0043803-Maagaard1" ref-type="bibr">[37]</xref>.</p><p>With respect to genotypic mtDNA variation, a study from the Multicenter AIDS Cohort
Study (MACS) recently reported that mtDNA variants were associated with progression
to AIDS and/or death in untreated, HIV-1-infected Caucasians <xref rid="pone.0043803-Hendrickson1" ref-type="bibr">[38]</xref>. We previously reported
associations between several mtDNA SNPs- and with the major African mtDNA haplogroup
L2 defined by several of these SNPs- and magnitude of CD4 T cell recovery after ART
initiation in non-Hispanic black participants in AIDS Clinical Trials Group (ACTG)
study 384 <xref rid="pone.0043803-Grady1" ref-type="bibr">[39]</xref>. It
is plausible that functional variation in mtDNA would influence T cell dynamics such
as apoptosis in response to environmental stressors (e.g. HIV infection and/or ART).
We hypothesized that among individuals with control of HIV replication following
initiation of ART, mtDNA variation would influence CD4 count recovery through
mechanisms that modulate the efficiency of CD4 cell proliferation, one of these
being T cell activation. In ACTG 384, persistent T cell activation was associated
with impaired CD4 recovery <xref rid="pone.0043803-Gandhi1" ref-type="bibr">[17]</xref>. To more fully characterize relationships between
mitochondrial genomics, T cell activation, and CD4 count recovery, we utilized mtDNA
sequence data and comprehensive immunologic data from a subset of ACTG 384
participants.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Ethics Statement</title><p>All ACTG 384 sites obtained local institutional review board (IRB) approval, and
all study subjects provided written, informed consent. The ACTG Human DNA
Repository (HDR) protocol (A5128) underwent separate IRB review at each ACTG
site, and subjects provided separate written, informed consent for inclusion of
samples in the HDR. The Vanderbilt Committee for the Protection of Human
Subjects and the ACTG approved the use of de-identified genetic and clinical
data used in these analyses.</p></sec><sec id="s2b"><title>Study Population</title><p>ACTG 384 (NCT00000919) was a multicenter, double-blind, prospective randomized
clinical trial comparing the efficacy of ART regimens consisting of three or
four drugs in antiretroviral-na&#x000ef;ve adults <xref rid="pone.0043803-Robbins2" ref-type="bibr">[40]</xref>&#x02013;<xref rid="pone.0043803-Shafer1" ref-type="bibr">[41]</xref>.
Participants were randomized to one of six treatment arms consisting of either
didanosine and stavudine or zidovudine and lamivudine combined with either
efavirenz, nelfinavir of both. A secondary end point of ACTG 384 was change in
CD4 cell count from baseline over 48, 96 and 144 weeks. A subset of individuals
underwent comprehensive immunologic assessments including proportions of memory
(CD45RO+/CD45RA&#x02212;) and na&#x000ef;ve (CD45RA+/CD62L+) CD4 cells
and activated (CD38+/HLA-DR+) T cells by flow cytometry <xref rid="pone.0043803-Gandhi1" ref-type="bibr">[17]</xref>. Baseline
characteristics for the subjects undergoing comprehensive immunologic
assessments were not different than the overall study population, with the
exception of inclusion of fewer Hispanic individuals <xref rid="pone.0043803-Gandhi1" ref-type="bibr">[17]</xref>. For the current study,
absolute CD4 counts and immunologic T cell assessments at baseline and week 48
from self-reported non-Hispanic black ACTG 384 participants who consented to
provide DNA to the ACTG HDR <xref rid="pone.0043803-Haas2" ref-type="bibr">[42]</xref> were analyzed. Individuals with HIV-1 RNA &#x02265;400
copies/mL at week 48 were excluded from analyses. Previous publications have
reported results from genetic association analysis in the ACTG 384 cohort, and
demonstrated no significant differences between ACTG participants who provided
DNA as part of the HDR and those who did not <xref rid="pone.0043803-Hulgan1" ref-type="bibr">[43]</xref>&#x02013;<xref rid="pone.0043803-Motsinger1" ref-type="bibr">[45]</xref>.</p></sec><sec id="s2c"><title>Mitochondrial DNA Isolation and Sequencing</title><p>DNA was isolated from study participants using PUREGENE (Gentra Systems Inc.,
Minneapolis, MN, USA). Full mtDNA sequencing was performed using the GeneChip
Human Mitochondrial Resequencing Array v2.0 (Affymetrix, Inc., Santa Clara, CA,
USA) <xref rid="pone.0043803-Maitra1" ref-type="bibr">[46]</xref>.
Mitochondrial DNA variants were defined by comparison with the revised Cambridge
Reference Sequence (rCRS) <xref rid="pone.0043803-Andrews1" ref-type="bibr">[47]</xref>. Haplogroups were assigned using Herrnstadt
classification <xref rid="pone.0043803-Herrnstadt1" ref-type="bibr">[48]</xref>, and collapsed into higher branch haplogroups for
analyses.</p></sec><sec id="s2d"><title>Statistical Analysis</title><p>The primary outcome of interest was change in percentage CD4 cell activation at
week 48. Additional outcomes of interest included baseline and 48 week changes
in other CD4 cell immunologic parameters, and CD8 cell counts and activation.
Baseline parameters were compared by haplogroups using Wilcoxon ranksum,
Fisher&#x02019;s exact, or chi-squared tests as appropriate. Wilcoxon ranksum test
was used to compare distribution of the outcomes by major African mtDNA
haplogroups. Multivariate linear regression was used to assess associations
between mtDNA haplogroups and CD4 cell activation adjusting for baseline age,
absolute CD4 count, HIV RNA, and na&#x000ef;ve-to-memory CD4 cell ratio. In the
primary and immunologic analyses of ACTG 384 <xref rid="pone.0043803-Gandhi1" ref-type="bibr">[17]</xref>, <xref rid="pone.0043803-Robbins2" ref-type="bibr">[40]</xref>, ART regimen was not found
to be a significant predictor of CD4 cell recovery following ART initiation and
thus was not adjusted for during analysis. Secondary outcomes included an
increase of &#x02265;100 CD4 cells/mm<sup>3</sup> at week 48. In order to maximize
power, primary analyses compared non-Hispanic black persons belonging to the L2
major haplogroup with all other non-Hispanic blacks. We also explored
differences between L2 and other individual major haplogroups L1 and L3.
Analyses were performed using STATA/SE 10.1 (StataCorp, College Station,
TX).</p></sec></sec><sec id="s3"><title>Results</title><p>ACTG 384 enrolled a total of 980 participants, 35% of whom were
self-identified non-Hispanic black race/ethnicity <xref rid="pone.0043803-Robbins2" ref-type="bibr">[40]</xref>. Of these, 623 (64%)
underwent comprehensive immunophenotyping; 39% of non-Hispanic black
race/ethnicity <xref rid="pone.0043803-Gandhi1" ref-type="bibr">[17]</xref>. For initial mtDNA analyses, 423 participants (126
[30%] non-Hispanic black) had mtDNA sequencing that passed all
genotyping quality filters, HIV RNA &#x0003c;400 copies/mL at week 48, and CD4 cell
counts available <xref rid="pone.0043803-Grady1" ref-type="bibr">[39]</xref>. Analyses presented here include 104 of these 126
non-Hispanic black participants with available T cell activation data. Baseline
demographics, T cell immunologic assessments, and randomized ART for these subjects
are shown in <xref ref-type="table" rid="pone-0043803-t001">Table 1</xref>. The
median age was 37 years (range 17, 72). Median baseline CD4 count was 283
cells/mm<sup>3</sup> (interquartile range [IQR] 111, 453);
log<sub>10</sub> HIV-1 copies/mL was 4.8 (IQR 4.1, 5.4), and percentage
activated CD4 and CD8 cells were 15 (IQR 8, 29) and 45 (IQR 33, 58), respectively.
Baseline na&#x000ef;ve-to-memory cell ratio was available for 91 (88%) subjects,
with a median of 0.47 (IQR 0.19, 0.87) among these. CD4 cells correlated with
percentage activated CD4 cells at baseline (rho&#x0200a;=&#x0200a;&#x02212;0.68;
p&#x0003c;0.001) and week 48 (&#x02212;0.53; p&#x0003c;0.001).</p><table-wrap id="pone-0043803-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0043803.t001</object-id><label>Table 1</label><caption><title>Baseline demographic data, T cell parameters, HIV RNA, and ART
randomization arms among the black, non-Hispanic ACTG 384 population with
baseline CD4 activation markers and 48 week HIV RNA &#x0003c;400 copies/mL, total
and by African L2 and non-L2 mtDNA haplogroups.</title></caption><alternatives><graphic id="pone-0043803-t001-1" xlink:href="pone.0043803.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Parameter</td><td align="left" rowspan="1" colspan="1">Total (N&#x0200a;=&#x0200a;104)</td><td align="left" rowspan="1" colspan="1">L2 (N&#x0200a;=&#x0200a;31)</td><td align="left" rowspan="1" colspan="1">Non-L2 (N&#x0200a;=&#x0200a;73)</td><td align="left" rowspan="1" colspan="1">p-value<xref ref-type="table-fn" rid="nt102">a</xref>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">37 (32, 46)</td><td align="left" rowspan="1" colspan="1">35 (31, 43)</td><td align="left" rowspan="1" colspan="1">39 (32, 46)</td><td align="left" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Female sex, N (%)</td><td align="left" rowspan="1" colspan="1">29 (28)</td><td align="left" rowspan="1" colspan="1">6 (19)</td><td align="left" rowspan="1" colspan="1">23 (32)</td><td align="left" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4+ (cells/mm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">283 (111, 453)</td><td align="left" rowspan="1" colspan="1">299 (117, 469)</td><td align="left" rowspan="1" colspan="1">280 (105, 420)</td><td align="left" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">Na&#x000ef;ve CD4+ (cells/mm<sup>3</sup>)
[N&#x0200a;=&#x0200a;95]<xref ref-type="table-fn" rid="nt103">b</xref>
</td><td align="left" rowspan="1" colspan="1">78 (14, 168)</td><td align="left" rowspan="1" colspan="1">60 (16, 139)</td><td align="left" rowspan="1" colspan="1">86 (14, 186)</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Memory CD4+ (cells/mm<sup>3</sup>)
[N&#x0200a;=&#x0200a;91]<xref ref-type="table-fn" rid="nt103">b</xref>
</td><td align="left" rowspan="1" colspan="1">154 (53, 238)</td><td align="left" rowspan="1" colspan="1">154 (97, 352)</td><td align="left" rowspan="1" colspan="1">154 (41, 217)</td><td align="left" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Na&#x000ef;ve/memory CD4+ cell
[N&#x0200a;=&#x0200a;91]<xref ref-type="table-fn" rid="nt103">b</xref>
</td><td align="left" rowspan="1" colspan="1">0.47 (0.19, 0.87)</td><td align="left" rowspan="1" colspan="1">0.41 (0.13, 0.72)</td><td align="left" rowspan="1" colspan="1">0.48 (0.22, 1.00)</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4+ CD38+/DR+ (cells)
[N&#x0200a;=&#x0200a;95]<xref ref-type="table-fn" rid="nt103">b</xref>
</td><td align="left" rowspan="1" colspan="1">31 (15, 46)</td><td align="left" rowspan="1" colspan="1">25 (15, 40)</td><td align="left" rowspan="1" colspan="1">34 (17, 51)</td><td align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4+ CD38+/DR+ (%)</td><td align="left" rowspan="1" colspan="1">15 (8, 29)</td><td align="left" rowspan="1" colspan="1">12 (6, 22)</td><td align="left" rowspan="1" colspan="1">17 (8, 32)</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8+ (cells/mm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">777 (471, 1212)</td><td align="left" rowspan="1" colspan="1">907 (436, 1349)</td><td align="left" rowspan="1" colspan="1">775 (481, 1101)</td><td align="left" rowspan="1" colspan="1">0.80</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8+ CD38+/DR+ (cells)
[N&#x0200a;=&#x0200a;95]<xref ref-type="table-fn" rid="nt103">b</xref>
</td><td align="left" rowspan="1" colspan="1">315 (183, 548)</td><td align="left" rowspan="1" colspan="1">301 (137, 521)</td><td align="left" rowspan="1" colspan="1">343 (221, 548)</td><td align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8+ CD38+/DR+ (%)</td><td align="left" rowspan="1" colspan="1">45 (33, 58)</td><td align="left" rowspan="1" colspan="1">41 (26, 54)</td><td align="left" rowspan="1" colspan="1">47 (35, 59)</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV RNA</td><td align="left" rowspan="1" colspan="1">4.8 (4.1, 5.4)</td><td align="left" rowspan="1" colspan="1">4.8 (4.1, 5.3)</td><td align="left" rowspan="1" colspan="1">4.8 (4.0, 5.4)</td><td align="left" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" rowspan="1" colspan="1">Randomized ART, N (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ZDV+3TC<xref ref-type="table-fn" rid="nt104">c</xref>
</td><td align="left" rowspan="1" colspan="1">56 (54)</td><td align="left" rowspan="1" colspan="1">20 (65)</td><td align="left" rowspan="1" colspan="1">36 (49)</td><td align="left" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">NFV</td><td align="left" rowspan="1" colspan="1">17 (30)</td><td align="left" rowspan="1" colspan="1">6 (30)</td><td align="left" rowspan="1" colspan="1">11 (31)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">EFV</td><td align="left" rowspan="1" colspan="1">16 (29)</td><td align="left" rowspan="1" colspan="1">5 (25)</td><td align="left" rowspan="1" colspan="1">11 (31)</td><td align="left" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" rowspan="1" colspan="1">NFV+EFV</td><td align="left" rowspan="1" colspan="1">23 (41)</td><td align="left" rowspan="1" colspan="1">9 (45)</td><td align="left" rowspan="1" colspan="1">14 (39)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ddI+d4T<xref ref-type="table-fn" rid="nt104">c</xref>
</td><td align="left" rowspan="1" colspan="1">48 (46)</td><td align="left" rowspan="1" colspan="1">11 (35)</td><td align="left" rowspan="1" colspan="1">37 (51)</td><td align="left" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">NFV</td><td align="left" rowspan="1" colspan="1">13 (27)</td><td align="left" rowspan="1" colspan="1">4 (36)</td><td align="left" rowspan="1" colspan="1">9 (24)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">EFV</td><td align="left" rowspan="1" colspan="1">16 (33)</td><td align="left" rowspan="1" colspan="1">6 (55)</td><td align="left" rowspan="1" colspan="1">10 (29)</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">NFV+EFV</td><td align="left" rowspan="1" colspan="1">19 (40)</td><td align="left" rowspan="1" colspan="1">1 (9)</td><td align="left" rowspan="1" colspan="1">18 (49)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><p>Data are median (IQR) except where noted.</p></fn><fn id="nt102"><label>a</label><p>Wilcoxon ranksum, Fisher&#x02019;s exact, or Pearson Chi<sup>2</sup> tests,
L2 vs. non-L2;</p></fn><fn id="nt103"><label>b</label><p>N with available baseline data shown;</p></fn><fn id="nt104"><label>c</label><p>p-values for NRTI backbone comparison shown.</p></fn></table-wrap-foot></table-wrap><p>Haplogroup distributions (including subhaplogroups) are shown in <xref ref-type="table" rid="pone-0043803-t002">Table 2</xref>. Major African
haplogroups included L1 (N&#x0200a;=&#x0200a;25 [24%]), L2
(N&#x0200a;=&#x0200a;31 [30%]), and L3 (32
[31%]). Non-African haplogroups were observed in 14 (13%)
individuals included in analyses of non-L2 comparison groups. Secondary analyses
limited to persons having African haplogroups yielded similar results (data not
shown). Baseline age, absolute CD4 count, and plasma HIV RNA were not statistically
different between haplogroup L2 individuals and others (<xref ref-type="table" rid="pone-0043803-t001">Table 1</xref>). Randomized NRTIs did not differ
statistically by haplogroup (p&#x0200a;=&#x0200a;0.20), but L2 individuals
randomized to didanosine plus stavudine tended to be randomized to the efavirenz arm
more often than non-L2 individuals (p&#x0200a;=&#x0200a;0.06).</p><table-wrap id="pone-0043803-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0043803.t002</object-id><label>Table 2</label><caption><title>Mitochondrial DNA haplogroup frequencies among black, non-Hispanic ACTG
384 participants.</title></caption><alternatives><graphic id="pone-0043803-t002-2" xlink:href="pone.0043803.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Haplogroup/Subhaplogroup- N (%)<xref ref-type="table-fn" rid="nt105">a</xref>
</td><td align="left" rowspan="1" colspan="1">Total non-Hispanic black with mtDNA sequence data
(N&#x0200a;=&#x0200a;126) <xref rid="pone.0043803-Grady1" ref-type="bibr">[39]</xref>
</td><td align="left" rowspan="1" colspan="1">Non-Hispanic black with mtDNA sequence and baseline
CD4+ activation data (N&#x0200a;=&#x0200a;104)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">African Haplogroups</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">L1</td><td align="left" rowspan="1" colspan="1">31 (25)</td><td align="left" rowspan="1" colspan="1">25 (24)</td></tr><tr><td align="left" rowspan="1" colspan="1">L1a</td><td align="left" rowspan="1" colspan="1">7 (6)</td><td align="left" rowspan="1" colspan="1">4 (4)</td></tr><tr><td align="left" rowspan="1" colspan="1">L1b</td><td align="left" rowspan="1" colspan="1">10 (8)</td><td align="left" rowspan="1" colspan="1">9 (9)</td></tr><tr><td align="left" rowspan="1" colspan="1">L1c</td><td align="left" rowspan="1" colspan="1">14 (11)</td><td align="left" rowspan="1" colspan="1">12 (12)</td></tr><tr><td align="left" rowspan="1" colspan="1">L1/L2</td><td align="left" rowspan="1" colspan="1">2 (2)</td><td align="left" rowspan="1" colspan="1">2 (2)</td></tr><tr><td align="left" rowspan="1" colspan="1">L2</td><td align="left" rowspan="1" colspan="1">40 (32)</td><td align="left" rowspan="1" colspan="1">31 (30)</td></tr><tr><td align="left" rowspan="1" colspan="1">L2a</td><td align="left" rowspan="1" colspan="1">25 (20)</td><td align="left" rowspan="1" colspan="1">22 (21)</td></tr><tr><td align="left" rowspan="1" colspan="1">L2b</td><td align="left" rowspan="1" colspan="1">15 (12)</td><td align="left" rowspan="1" colspan="1">9 (9)</td></tr><tr><td align="left" rowspan="1" colspan="1">L3</td><td align="left" rowspan="1" colspan="1">36 (29)<xref ref-type="table-fn" rid="nt106">b</xref>
</td><td align="left" rowspan="1" colspan="1">32 (31)<xref ref-type="table-fn" rid="nt106">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">L3b</td><td align="left" rowspan="1" colspan="1">12 (10)</td><td align="left" rowspan="1" colspan="1">11 (11)</td></tr><tr><td align="left" rowspan="1" colspan="1">L3e</td><td align="left" rowspan="1" colspan="1">8 (6)</td><td align="left" rowspan="1" colspan="1">7 (7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-African Haplogroups</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">4 (3)</td><td align="left" rowspan="1" colspan="1">3 (3)</td></tr><tr><td align="left" rowspan="1" colspan="1">H2</td><td align="left" rowspan="1" colspan="1">4 (3)</td><td align="left" rowspan="1" colspan="1">4 (4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Others<xref ref-type="table-fn" rid="nt107">c</xref>
</td><td align="left" rowspan="1" colspan="1">9 (7)</td><td align="left" rowspan="1" colspan="1">7 (7)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label>a</label><p>Totals may not &#x0200a;=&#x0200a;100% due to rounding;</p></fn><fn id="nt106"><label>b</label><p>Total includes haplogroup L3, not sub-haplogrouped;</p></fn><fn id="nt107"><label>c</label><p>Includes haplogroups H, I, J1, T1, T2b, U6, U9 (N&#x02264;2 each).</p></fn></table-wrap-foot></table-wrap><p>When comparing mtDNA haplogroup L2 with all other haplogroups (<xref ref-type="table" rid="pone-0043803-t001">Table 1</xref>), baseline median percentage activated
(CD38+/HLA-DR+) CD4 cells was significantly lower (12% [IQR 6,
22] vs. 17% <xref rid="pone.0043803-Soria1" ref-type="bibr">[8]</xref>, <xref rid="pone.0043803-DeBenedictis1" ref-type="bibr">[32]</xref>; p&#x0200a;=&#x0200a;0.03) in persons belonging to
the L2 haplogroup. Median absolute activated CD4 cells was lower (25 <xref rid="pone.0043803-Goicoechea1" ref-type="bibr">[15]</xref>, <xref rid="pone.0043803-Robbins2" ref-type="bibr">[40]</xref> vs. 34 <xref rid="pone.0043803-Gandhi1" ref-type="bibr">[17]</xref>, <xref rid="pone.0043803-Miura1" ref-type="bibr">[51]</xref>
cells/mm<sup>3</sup>; p&#x0200a;=&#x0200a;0.11), but was not statistically
different. Median percentage activated CD8 cells also tended to be lower (41%
<xref rid="pone.0043803-Badley1" ref-type="bibr">[26]</xref>, <xref rid="pone.0043803-Karamchand1" ref-type="bibr">[54]</xref> vs.
47% <xref rid="pone.0043803-Raule1" ref-type="bibr">[35]</xref>,
<xref rid="pone.0043803-Geromel1" ref-type="bibr">[59]</xref>;
p&#x0200a;=&#x0200a;0.06). After 48 weeks of ART, median CD4 cells was not
statistically different in the L2 versus non-L2 haplogroups (399 [IQR 168,
670] vs. 472 [292, 732]; p&#x0200a;=&#x0200a;0.13; <xref ref-type="table" rid="pone-0043803-t003">Table 3</xref>). However, the median
change from baseline was significantly less among L2 versus non-L2 haplogroups
(+95 [&#x02212;3, +182] cells vs. +178 [+105,
+312]; p&#x0200a;=&#x0200a;0.002; <xref ref-type="fig" rid="pone-0043803-g001">Figure 1A</xref>). Similarly, although 48 week
percentage activated CD4 cells did not differ (7% <xref rid="pone.0043803-Grabar1" ref-type="bibr">[4]</xref>, <xref rid="pone.0043803-Varbanov1" ref-type="bibr">[11]</xref> vs. 6% <xref rid="pone.0043803-Grabar1" ref-type="bibr">[4]</xref>, <xref rid="pone.0043803-Haas1" ref-type="bibr">[9]</xref>;
p&#x0200a;=&#x0200a;0.57), the median change in percentage activated CD4 cells
was significantly less in the L2 compared with the non-L2 haplogroups
(&#x02212;4% [&#x02212;8, &#x02212;2] vs. &#x02212;11%
[&#x02212;26, &#x02212;4]; p&#x0200a;=&#x0200a;0.01; <xref ref-type="fig" rid="pone-0043803-g001">Figure 1B</xref>). Correlations between CD4 cells and
percentage activated CD4 cells at baseline and week 48 were similar among L2 and
non-L2 haplogroups (data not shown).</p><table-wrap id="pone-0043803-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0043803.t003</object-id><label>Table 3</label><caption><title>T cell parameters at 48 weeks and 48 week changes among the black,
non-Hispanic ACTG 384 population with baseline CD4 activation markers and 48
week HIV RNA &#x0003c;400 copies/mL, total and by African L2 and non-L2 mtDNA
haplogroups.</title></caption><alternatives><graphic id="pone-0043803-t003-3" xlink:href="pone.0043803.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Parameter</td><td align="left" rowspan="1" colspan="1">Total non-Hispanic black
(N&#x0200a;=&#x0200a;104)</td><td colspan="2" align="left" rowspan="1">L2 (N&#x0200a;=&#x0200a;31)</td><td colspan="2" align="left" rowspan="1">Non-L2
(N&#x0200a;=&#x0200a;73)</td><td align="left" rowspan="1" colspan="1">p-value<xref ref-type="table-fn" rid="nt109">a</xref>
</td></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1">
<bold>Week 48</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4+ (cells/mm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">460 (230, 711)</td><td colspan="2" align="left" rowspan="1">399 (168, 670)</td><td colspan="2" align="left" rowspan="1">472 (292, 732)</td><td align="left" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Na&#x000ef;ve CD4+ (cells/mm<sup>3</sup>)
[N&#x0200a;=&#x0200a;98]<xref ref-type="table-fn" rid="nt110">b</xref>
</td><td align="left" rowspan="1" colspan="1">148 (70, 323)</td><td colspan="2" align="left" rowspan="1">96 (48, 253)</td><td colspan="2" align="left" rowspan="1">165 (79, 346)</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Memory CD4+ (cells/mm<sup>3</sup>)
[N&#x0200a;=&#x0200a;98]<xref ref-type="table-fn" rid="nt110">b</xref>
</td><td align="left" rowspan="1" colspan="1">247 (133, 326)</td><td colspan="2" align="left" rowspan="1">228 (113, 359)</td><td colspan="2" align="left" rowspan="1">251 (134, 317)</td><td align="left" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4+ CD38+/DR+ (cells)
[N&#x0200a;=&#x0200a;97]<xref ref-type="table-fn" rid="nt110">b</xref>
</td><td align="left" rowspan="1" colspan="1">24 (15, 43)</td><td colspan="2" align="left" rowspan="1">20 (12, 37)</td><td colspan="2" align="left" rowspan="1">24 (17, 44)</td><td align="left" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4+ CD38+/DR+ (%)
[N&#x0200a;=&#x0200a;97]<xref ref-type="table-fn" rid="nt110">b</xref>
</td><td align="left" rowspan="1" colspan="1">6 (4, 10)</td><td colspan="2" align="left" rowspan="1">7 (4, 11)</td><td colspan="2" align="left" rowspan="1">6 (4, 9)</td><td align="left" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8+ (cells/mm3)</td><td align="left" rowspan="1" colspan="1">812 (554, 1031)</td><td colspan="2" align="left" rowspan="1">726 (470&#x02013;914)</td><td colspan="2" align="left" rowspan="1">855 (575, 1072)</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8+ CD38+/DR+ (cells)
[N&#x0200a;=&#x0200a;99]<xref ref-type="table-fn" rid="nt110">b</xref>
</td><td align="left" rowspan="1" colspan="1">127 (88, 252)</td><td colspan="2" align="left" rowspan="1">115 (90, 182)</td><td colspan="2" align="left" rowspan="1">141 (88, 273)</td><td align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8+ CD38+/DR+ (%)
[N&#x0200a;=&#x0200a;112]<xref ref-type="table-fn" rid="nt110">b</xref>
</td><td align="left" rowspan="1" colspan="1">21 (13, 29)</td><td colspan="2" align="left" rowspan="1">20 (14, 28)</td><td colspan="2" align="left" rowspan="1">21 (11, 30)</td><td align="left" rowspan="1" colspan="1">0.87</td></tr><tr><td colspan="7" align="left" rowspan="1">
<bold>Week 48-Week 0</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4+ change (cells/mm<sup>3</sup>)</td><td colspan="2" align="left" rowspan="1">+135 (+79, +271)</td><td colspan="2" align="left" rowspan="1">+95 (&#x02212;3, +182)</td><td align="left" rowspan="1" colspan="1">+178 (+105,+312)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">N (%) with &#x02265;100 CD4 cell increase</td><td colspan="2" align="left" rowspan="1">68 (65)</td><td colspan="2" align="left" rowspan="1">13 (42)</td><td align="left" rowspan="1" colspan="1">55 (75)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Na&#x000ef;ve CD4+ change (cells)
[N&#x0200a;=&#x0200a;90]<xref ref-type="table-fn" rid="nt110">b</xref>
</td><td colspan="2" align="left" rowspan="1">+74 (+29, +161)</td><td colspan="2" align="left" rowspan="1">+43 (+20, +80)</td><td align="left" rowspan="1" colspan="1">+87 (+31, +171)</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Memory CD4+ change (cells)
[N&#x0200a;=&#x0200a;86]<xref ref-type="table-fn" rid="nt110">b</xref>
</td><td colspan="2" align="left" rowspan="1">+82 (+30, +135)</td><td colspan="2" align="left" rowspan="1">+50 (+15, +125)</td><td align="left" rowspan="1" colspan="1">+104 (+35, +139)</td><td align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4+ CD38+/DR+ change (cells)
[N&#x0200a;=&#x0200a;89]<xref ref-type="table-fn" rid="nt110">b</xref>
</td><td colspan="2" align="left" rowspan="1">&#x02212;2.3 (&#x02212;18, +10)</td><td colspan="2" align="left" rowspan="1">&#x02212;4.5 (&#x02212;11.8,
+13.7)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.3 (&#x02212;23.6, +7.5)</td><td align="left" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4+ CD38+/DR+ change (%)
[N&#x0200a;=&#x0200a;97]<xref ref-type="table-fn" rid="nt110">b</xref>
</td><td colspan="2" align="left" rowspan="1">&#x02212;8 (&#x02212;22, &#x02212;3)</td><td colspan="2" align="left" rowspan="1">&#x02212;4 (&#x02212;8, &#x02212;2)</td><td align="left" rowspan="1" colspan="1">&#x02212;11 (&#x02212;26, &#x02212;4)</td><td align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8+ change (cells/mm3)</td><td colspan="2" align="left" rowspan="1">&#x02212;67 (&#x02212;320, +223)</td><td colspan="2" align="left" rowspan="1">&#x02212;148 (&#x02212;540, +116)</td><td align="left" rowspan="1" colspan="1">&#x02212;61 (&#x02212;255, +260)</td><td align="left" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8+ CD38+/DR+ change (cells)
[N&#x0200a;=&#x0200a;90]<xref ref-type="table-fn" rid="nt110">b</xref>
</td><td colspan="2" align="left" rowspan="1">&#x02212;188 (&#x02212;324, &#x02212;51)</td><td colspan="2" align="left" rowspan="1">&#x02212;143 (&#x02212;307, &#x02212;48)</td><td align="left" rowspan="1" colspan="1">&#x02212;204 (&#x02212;333, &#x02212;60)</td><td align="left" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8+ CD38+/DR+ change (%)
[N&#x0200a;=&#x0200a;99]<xref ref-type="table-fn" rid="nt110">b</xref>
</td><td colspan="2" align="left" rowspan="1">&#x02212;26 (&#x02212;33, &#x02212;13)</td><td colspan="2" align="left" rowspan="1">&#x02212;17 (&#x02212;33, &#x02212;10)</td><td align="left" rowspan="1" colspan="1">&#x02212;27 (&#x02212;33, &#x02212;17)</td><td align="left" rowspan="1" colspan="1">0.09</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt108"><p>Data are median (IQR) except where noted.</p></fn><fn id="nt109"><label>a</label><p>Wilcoxon ranksum, Fisher&#x02019;s exact, or Pearson Chi<sup>2</sup> tests,
L2 vs. non-L2;</p></fn><fn id="nt110"><label>b</label><p>N with available data shown.</p></fn></table-wrap-foot></table-wrap><fig id="pone-0043803-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0043803.g001</object-id><label>Figure 1</label><caption><title>Scatter plots of 48 week changes in CD4 cells (Panel A), and percentage
activated (CD38+/HLA-DR+) CD4 cells (Panel B).</title><p>Haplogroup L2 individuals had a significantly lower median increase in CD4
cells and a lower decrease in percentage activated CD4 cells. Unadjusted
p-values by Wilcoxon ranksum test shown. x-lines &#x0200a;=&#x0200a;
median; dashed lines&#x0200a;=&#x0200a;25<sup>th</sup> and
75<sup>th</sup> percentiles.</p></caption><graphic xlink:href="pone.0043803.g001"/></fig><p>Among other T cell measures, median na&#x000ef;ve CD4 cells
(p&#x0200a;=&#x0200a;0.06) and absolute CD8 cell counts
(p&#x0200a;=&#x0200a;0.07) at 48 weeks both tended to be lower among
individuals belonging to the L2 haplogroup (<xref ref-type="table" rid="pone-0043803-t003">Table 3</xref>). Median week 48 increases in na&#x000ef;ve
CD4 cells also tended to be lower (+43 [+20, +80] vs.
+87 [+31, +171]; p&#x0200a;=&#x0200a;0.06) among
haplogroup L2 individuals, as were decreases in activated CD8 cells
(&#x02212;17% [&#x02212;33, &#x02212;10]; &#x02212;27 [&#x02212;33,
&#x02212;17]; p&#x0200a;=&#x0200a;0.09), but these differences were not
statistically significant. As observed in our earlier study, <xref rid="pone.0043803-Grady1" ref-type="bibr">[39]</xref> persons in this sub-analysis
belonging to haplogroup L2 were significantly less likely to have an increase of
&#x02265;100 CD4 cells over the first 48 weeks of suppressive ART compared to non-L2
individuals (42% vs. 75%; p&#x0200a;=&#x0200a;0.002).</p><p>In separate multivariate models, associations between mtDNA haplogroup L2 and
baseline (pre-ART) and 48-week changes in percentage activated CD4 cells were
assessed with adjustment for baseline age, absolute CD4 count, HIV RNA, and
na&#x000ef;ve-to-memory CD4 cell ratio. <xref rid="pone.0043803-Gandhi1" ref-type="bibr">[17]</xref> In both models, baseline CD4
count was strongly associated with percentage activated CD4 cells (p&#x0003c;0.001; <xref ref-type="table" rid="pone-0043803-t004">Table 4</xref>). Haplogroup L2 was also
associated with lower baseline (&#x003b2;&#x0200a;=&#x0200a;&#x02212;6.7
[95% CI &#x02212;12.8, &#x02212;0.50]; p&#x0200a;=&#x0200a;0.035)
and smaller 48-week change (&#x003b2;&#x0200a;=&#x0200a;7.5 [1.6,13.5];
p&#x0200a;=&#x0200a;0.013) in percentage activated CD4 cells.</p><table-wrap id="pone-0043803-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0043803.t004</object-id><label>Table 4</label><caption><title>Multivariate models of associations between baseline covariates,
haplogroup L2, and percentage CD4 cell activation.</title></caption><alternatives><graphic id="pone-0043803-t004-4" xlink:href="pone.0043803.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Model 1: Baseline % activated
CD4 cells (N&#x0200a;=&#x0200a;91)</td><td colspan="2" align="left" rowspan="1">Model 2: 48 week change in %
activated CD4 cells (N&#x0200a;=&#x0200a;85)</td></tr><tr><td align="left" rowspan="1" colspan="1">Covariates</td><td align="left" rowspan="1" colspan="1">&#x003b2; (95% CI)</td><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">&#x003b2; (95% CI)</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (per year increase)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.02 (&#x02212;0.29, +0.25)</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">+0.10 (&#x02212;0.15, +0.36)</td><td align="left" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline plasma HIV RNA (per log<sub>10</sub>
copies/mL increase)</td><td align="left" rowspan="1" colspan="1">+2.04 (&#x02212;1.53, +5.61)</td><td align="left" rowspan="1" colspan="1">0.26</td><td align="left" rowspan="1" colspan="1">&#x02212;2.11 (&#x02212;5.46, +1.23)</td><td align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">Na&#x000ef;ve-to-memory CD4 cell ratio (per unit
increase)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.46 (&#x02212;1.40, +0.48)</td><td align="left" rowspan="1" colspan="1">0.33</td><td align="left" rowspan="1" colspan="1">+0.24 (&#x02212;0.62, +1.10)</td><td align="left" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline CD4 cells (per 10 cell increase)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.40 (&#x02212;0.54, &#x02212;0.25)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">+0.27 (+0.13, +0.40)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Haplogroup L2 (vs. others)</td><td align="left" rowspan="1" colspan="1">&#x02212;6.67 (&#x02212;12.84, &#x02212;0.50)</td><td align="left" rowspan="1" colspan="1">0.035</td><td align="left" rowspan="1" colspan="1">+7.54 (+1.62, +13.46)</td><td align="left" rowspan="1" colspan="1">0.013</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s4"><title>Discussion</title><p>This analysis expands a previous study of mitochondrial genomic predictors of CD4
cell recovery in ACTG Study 384 <xref rid="pone.0043803-Grady1" ref-type="bibr">[39]</xref>. Differences in T cell subsets and activation markers
were observed within the African mtDNA haplogroup that also demonstrated impaired
CD4 cell recovery despite suppressed HIV RNA after 48 weeks on ART. The most notable
differences included lower CD4 cell activation at baseline despite similar absolute
CD4 counts and HIV RNA, and less decrease in percentage activated CD4 cells together
with a less robust increase in absolute CD4 cells after 48 weeks of ART (as was
previously reported <xref rid="pone.0043803-Grady1" ref-type="bibr">[39]</xref>). There were also several intriguing trends- including in
na&#x000ef;ve CD4 cell populations, and absolute and activated CD8 cell subsets- that
did not reach statistical significance in this small sample but deserve additional
study. Although replication in larger studies and mechanistic validation are needed
to confirm these findings, we interpret these results as suggesting that mtDNA
variation among these non-Hispanic black clinical trial participants influenced the
magnitude of CD4 cell recovery in the first year after ART by modulating T cell
activation through as-yet-unknown mechanisms. This modulation was independent of
other baseline predictors of short-term CD4 recovery, including age, CD4 count, and
na&#x000ef;ve-to-memory CD4 cell ratio.</p><p>The role of the mitochondrion as an apoptotic regulator is well recognized, and its
specific relevance in T cells during HIV-infection has been studied <xref rid="pone.0043803-Garg1" ref-type="bibr">[49]</xref>. In a recent
study, peripheral blood mononuclear cells (PBMCs) from HIV-infected long-term
non-progressors demonstrated less mitochondrial dysfunction and
mitochondria-mediated apoptosis than typical progressors <xref rid="pone.0043803-Peraire1" ref-type="bibr">[50]</xref>. Studies have also observed
reduced mtDNA quantity in PBMCs from ART-na&#x000ef;ve, HIV-infected compared with
HIV-negative individuals <xref rid="pone.0043803-Maagaard1" ref-type="bibr">[37]</xref>, <xref rid="pone.0043803-Miura1" ref-type="bibr">[51]</xref>. One study reported decreased mtDNA that correlated with
increased T cell activation in chronically infected, untreated men <xref rid="pone.0043803-Casula1" ref-type="bibr">[36]</xref>. Another found
decreased mitochondrial membrane potential and increased apoptosis in PBMCs from
HIV-infected, ART-naive compared with uninfected subjects <xref rid="pone.0043803-Sternfeld1" ref-type="bibr">[52]</xref>&#x02013;<xref rid="pone.0043803-Sternfeld2" ref-type="bibr">[53]</xref>. These measures correlated
with each other, and lower mitochondrial membrane potential correlated with lower
CD4 T cell counts. In black South Africans <xref rid="pone.0043803-Karamchand1" ref-type="bibr">[54]</xref>, total T cell mitochondrial
depolarization and CD4 T cell apoptosis were increased in ART-naive compared with
treated subjects, and a positive correlation between these parameters was observed
among treated subjects, suggesting relationships between mitochondrial function and
T cell apoptosis in patients. Finally, recent work from one group has characterized
mechanisms by which mitochondria might regulate activation in Jurkat T cell lines in
the absence of HIV infection <xref rid="pone.0043803-Quintana1" ref-type="bibr">[55]</xref>&#x02013;<xref rid="pone.0043803-Quintana2" ref-type="bibr">[56]</xref>.Taken together, these data strongly suggest that adverse
mitochondrial phenotypes prior to ART can contribute to peripheral T cell activation
and apoptosis. Published data on the direct effects of mtDNA variation on cellular
apoptosis are still limited, but include a murine model of mtDNA depletion <xref rid="pone.0043803-Wang1" ref-type="bibr">[57]</xref>, and a small
study of patients with mtDNA tRNA point mutations showing an increase in apoptotic
muscle fibers (by TUNEL staining) <xref rid="pone.0043803-Mirabella1" ref-type="bibr">[58]</xref>. An <italic>in
vitro</italic> study in fibroblasts demonstrated massive ROS-induced apoptosis
in the presence of a mtDNA point mutation <xref rid="pone.0043803-Geromel1" ref-type="bibr">[59]</xref>.</p><p>Based on this emerging literature and our results, one could speculate regarding
several possible mechanisms by which mtDNA variants (in this case, those
specifically marking the L2 haplogroup) might influence CD4 cell recovery. First, T
cells harboring specific L2-associated mtDNA variants may have differential ability
to become and/or remain activated in the presence of antigenic stimulation. Second,
mtDNA variation could lead to differential susceptibility to cell death (via the
intrinsic apoptotic pathway) in the setting of chronic T cell activation prior to
suppression of HIV replication with ART. This could lead to a lower percentage of
activated T cells prior to starting ART, as was observed here. We also observed a
less robust decrease in percentage activated CD4 (and to a lesser extent, CD8) cells
during the first 48 weeks of ART. If a greater proportion of activated cells
progress to apoptotic cell death among persons with haplogroup L2, this could
explain a less robust gain in absolute CD4 cells over the same time period. This
less robust CD4 cell increase may also be related to fewer numbers of na&#x000ef;ve CD4
cells- an important component of CD4 recovery after suppression of viral replication
in this population <xref rid="pone.0043803-Gandhi1" ref-type="bibr">[17]</xref>, <xref rid="pone.0043803-Robbins1" ref-type="bibr">[22]</xref>- both at baseline and after 48 weeks of ART.</p><p>CD4 cell activation has been associated with CD4 cell recovery <xref rid="pone.0043803-Goicoechea1" ref-type="bibr">[15]</xref>&#x02013;<xref rid="pone.0043803-Massanella1" ref-type="bibr">[16]</xref>. In the overall immunologic
analysis of this population <xref rid="pone.0043803-Gandhi1" ref-type="bibr">[17]</xref>, there was no correlation between baseline CD4 cell
activation and CD4 recovery on ART, but higher CD4 and CD8 activation at week 48
correlated with CD4 recovery at week 48. Although the direction of associations were
similar in our subgroup, we did not observe significant correlations between 48-week
CD4 or CD8 activation and CD4 recovery (data not shown), perhaps due to the smaller
sample size. However, absolute CD4 cells were strongly correlated with percentage
activated CD4 cells at both time points.</p><p>A recent analysis using data from several U.S. cohorts reported associations between
European haplogroups and increased prevalence of pre-ART progression to AIDS and/or
CD4 count &#x0003c;200 cells/mm<sup>3</sup> among Caucasians <xref rid="pone.0043803-Hendrickson1" ref-type="bibr">[38]</xref>. These findings are also
consistent with a role for mtDNA variation in CD4 T cell dynamics. Another study did
not find cross-sectional associations between mtDNA haplogroups and current CD4
counts or viral load among a population of predominantly ART-treated HIV-infected
Italians <xref rid="pone.0043803-Nasi2" ref-type="bibr">[60]</xref>. The
present study is, to our knowledge, the first to assess relationships between
<italic>ex vivo</italic> measures of T cell activation and mitochondrial genomic
variation in a population with longitudinal data from before and after ART.</p><p>Limitations of our data include a small sample size which may have impaired our
ability to detect less robust associations. We elected to use self-identified
race/ethnicity to define our analysis group instead of genetic ancestry. Secondary
analyses that included only non-Hispanic black individuals with an African L
haplogroup yielded similar results (data not shown). Because of the focused nature
of these analyses, results are not generalizable to other racial/ethnic groups. We
defined virologic suppression as HIV RNA &#x0003c;400 copies/mL; it is possible that
lower levels of viral replication influenced T cell activation in these subjects.
However, plasma viral load at week 48 (median [IQR] 1.38
[1.23&#x02013;1.53] log<sub>10</sub> copies/mL) was not correlated with
either CD4 or CD8 activation at week 48 or 48-week changes in activation (data not
shown). Additionally, in a secondary analysis of 89 (86%) persons with
48-week HIV RNA &#x0003c;50 copies/mL, results were also similar (data not shown). All
subjects included in these analyses received older NRTI combinations: stavudine plus
didanosine, or zidovudine plus lamivudine. Given the lack of association of CD4 cell
recovery with study arm in prior analyses of this population <xref rid="pone.0043803-Gandhi1" ref-type="bibr">[17]</xref>, <xref rid="pone.0043803-Robbins1" ref-type="bibr">[22]</xref>, <xref rid="pone.0043803-Robbins2" ref-type="bibr">[40]</xref>&#x02013;<xref rid="pone.0043803-Shafer1" ref-type="bibr">[41]</xref>, we did not include ART in
adjusted models, and do not believe observed relationships between mtDNA haplogroup
and T cell activation markers are explained by NRTI mitochondrial toxicity,
<italic>per se</italic>. Studies using data from cohorts of subjects exposed to
newer NRTIs will be necessary to confirm that relationships persist and are of
similar magnitude in this setting. Less robust CD4 cell recovery on ART has been
associated with HIV-related disease progression <xref rid="pone.0043803-Gutierrez1" ref-type="bibr">[2]</xref>, <xref rid="pone.0043803-Grabar1" ref-type="bibr">[4]</xref>, and with incidence of
non-AIDS-defining cancers in a cohort study that included some ACTG 384 participants
<xref rid="pone.0043803-Krishnan1" ref-type="bibr">[61]</xref>. Our
analyses did not include these outcome data, thus we cannot determine whether less
robust decreases in CD4 cell activation markers and/or CD4 cell increases observed
with the African L2 haplogroup over the first 48 weeks of suppressive ART impacted
long-term clinical outcomes. Lastly, although these results suggest that mtDNA
variation may influence T cell activation, we do not have direct functional measures
of mitochondrial oxidative phosphorylation or apoptosis in these subjects to provide
additional data on potential mechanisms. Future studies will include such
measures.</p><p>In summary, we report what is to our knowledge the first association between mtDNA
variation and measures of T cell activation in an HIV infected population. The
careful data and specimen collection as part of a prospective clinical trial is a
strength of these analyses. Replication of these results in independent clinical
trial datasets is needed, ideally including African populations where the L2
haplogroup is prevalent. Larger studies may also allow for more specific assessment
of mtDNA subhaplogroups and/or SNPs associated with even more pronounced differences
in CD4 recovery. Mechanistic studies of mitochondrial function within T cells are
feasible, and will be necessary to further confirm and characterize relationships
between mtDNA variants and T cell function. Ultimately, an improved understanding of
the role of mitochondria and mtDNA variation in T cell dynamics could lead to
improved decisions about when and in whom to initiate ART, and to targeted
therapeutic interventions that could augment CD4 recovery and its health benefits in
HIV-infected persons.</p></sec></body><back><ack><p>The authors gratefully acknowledge the many HIV-infected patients who participated in
ACTG study 384 and protocol A5128. We also acknowledge Laura Smeaton, Diana Ventura,
and Roy Matining (Harvard School of Public Health) for assistance with clinical data
from ACTG study 384.</p><p>Additional members of the ACTG 384 study leadership team included: Victor De
Gruttola (Harvard School of Public Health), Sally Snyder, Thomas Nevin (Social
&#x00026; Scientific Systems), Carla Pettinelli (National Institutes of Health),
Michael Dube (Indiana University), Margaret Fischl (Miami University), Robert
Delaphna (Howard University), Linda Gideon (Frontier Science and Technology
Foundation), Richard D&#x02019;Aquila (Vanderbilt University), Stefano Vella
(Istituto Superiore de Sanita), Thomas Merigan (Stanford University) and Martin
Hirsch (Harvard Medical School).</p></ack><ref-list><title>References</title><ref id="pone.0043803-Kitahata1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Kitahata</surname><given-names>MM</given-names></name>, <name><surname>Gange</surname><given-names>SJ</given-names></name>, <name><surname>Abraham</surname><given-names>AG</given-names></name>, <name><surname>Merriman</surname><given-names>B</given-names></name>, <name><surname>Saag</surname><given-names>MS</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Effect of early
versus deferred antiretroviral therapy for HIV on survival</article-title>.
<source>N Engl J Med</source>
<volume>360</volume>:
<fpage>1815</fpage>&#x02013;<lpage>1826</lpage>.<pub-id pub-id-type="pmid">19339714</pub-id></mixed-citation></ref><ref id="pone.0043803-Gutierrez1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Gutierrez</surname><given-names>F</given-names></name>, <name><surname>Padilla</surname><given-names>S</given-names></name>, <name><surname>Masia</surname><given-names>M</given-names></name>, <name><surname>Iribarren</surname><given-names>JA</given-names></name>, <name><surname>Moreno</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Clinical outcome
of HIV-infected patients with sustained virologic response to antiretroviral
therapy: long-term follow-up of a multicenter cohort</article-title>.
<source>PLoS ONE</source>
<volume>1</volume>: <fpage>e89</fpage>.<pub-id pub-id-type="pmid">17183720</pub-id></mixed-citation></ref><ref id="pone.0043803-Gazzola1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Gazzola</surname><given-names>L</given-names></name>, <name><surname>Tincati</surname><given-names>C</given-names></name>, <name><surname>Bellistri</surname><given-names>GM</given-names></name>, <name><surname>Monforte</surname><given-names>A</given-names></name>, <name><surname>Marchetti</surname><given-names>G</given-names></name> (<year>2009</year>) <article-title>The absence of CD4+ T cell count
recovery despite receipt of virologically suppressive highly active
antiretroviral therapy: clinical risk, immunological gaps, and therapeutic
options</article-title>. <source>Clin Infect Dis</source>
<volume>48</volume>:
<fpage>328</fpage>&#x02013;<lpage>337</lpage>.<pub-id pub-id-type="pmid">19123868</pub-id></mixed-citation></ref><ref id="pone.0043803-Grabar1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Grabar</surname><given-names>S</given-names></name>, <name><surname>Le Moing</surname><given-names>V</given-names></name>, <name><surname>Goujard</surname><given-names>C</given-names></name>, <name><surname>Leport</surname><given-names>C</given-names></name>, <name><surname>Kazatchkine</surname><given-names>MD</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>Clinical outcome
of patients with HIV-1 infection according to immunologic and virologic
response after 6 months of highly active antiretroviral
therapy</article-title>. <source>Ann Intern Med</source>
<volume>133</volume>:
<fpage>401</fpage>&#x02013;<lpage>410</lpage>.<pub-id pub-id-type="pmid">10975957</pub-id></mixed-citation></ref><ref id="pone.0043803-Rigato1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Rigato</surname><given-names>PO</given-names></name>, <name><surname>Hong</surname><given-names>MA</given-names></name>, <name><surname>Casseb</surname><given-names>J</given-names></name>, <name><surname>Ueda</surname><given-names>M</given-names></name>, <name><surname>de Castro</surname><given-names>I</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Better CD4+
T cell recovery in Brazilian HIV-infected individuals under HAART due to
cumulative carriage of SDF-1&#x02013;3&#x02032;A, CCR2-V64I, CCR5-D32 and
CCR5-promoter 59029A/G polymorphisms</article-title>. <source>Curr HIV
Res</source>
<volume>6</volume>:
<fpage>466</fpage>&#x02013;<lpage>473</lpage>.<pub-id pub-id-type="pmid">18855658</pub-id></mixed-citation></ref><ref id="pone.0043803-Ahuja1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Ahuja</surname><given-names>SK</given-names></name>, <name><surname>Kulkarni</surname><given-names>H</given-names></name>, <name><surname>Catano</surname><given-names>G</given-names></name>, <name><surname>Agan</surname><given-names>BK</given-names></name>, <name><surname>Camargo</surname><given-names>JF</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>CCL3L1-CCR5
genotype influences durability of immune recovery during antiretroviral
therapy of HIV-1-infected individuals</article-title>. <source>Nat
Med</source>
<volume>14</volume>:
<fpage>413</fpage>&#x02013;<lpage>420</lpage>.<pub-id pub-id-type="pmid">18376407</pub-id></mixed-citation></ref><ref id="pone.0043803-Rauch1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Rauch</surname><given-names>A</given-names></name>, <name><surname>Nolan</surname><given-names>D</given-names></name>, <name><surname>Furrer</surname><given-names>H</given-names></name>, <name><surname>McKinnon</surname><given-names>E</given-names></name>, <name><surname>John</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>HLA-Bw4
homozygosity is associated with an impaired CD4 T cell recovery after
initiation of antiretroviral therapy</article-title>. <source>Clin Infect
Dis</source>
<volume>46</volume>:
<fpage>1921</fpage>&#x02013;<lpage>1925</lpage>.<pub-id pub-id-type="pmid">18466093</pub-id></mixed-citation></ref><ref id="pone.0043803-Soria1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Soria</surname><given-names>A</given-names></name>, <name><surname>Guerini</surname><given-names>FR</given-names></name>, <name><surname>Bandera</surname><given-names>A</given-names></name>, <name><surname>Bolognesi</surname><given-names>E</given-names></name>, <name><surname>Uglietti</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>KIR-HLA
Genotypes in HIV-Infected Patients Lacking Immunological Recovery despite
Effective Antiretroviral Therapy</article-title>. <source>PLoS One</source>
<volume>6</volume>: <fpage>e27349</fpage>.<pub-id pub-id-type="pmid">22073315</pub-id></mixed-citation></ref><ref id="pone.0043803-Haas1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Haas</surname><given-names>DW</given-names></name>, <name><surname>Geraghty</surname><given-names>DE</given-names></name>, <name><surname>Andersen</surname><given-names>J</given-names></name>, <name><surname>Mar</surname><given-names>J</given-names></name>, <name><surname>Motsinger</surname><given-names>AA</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Immunogenetics
of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS
Clinical Trials Group study</article-title>. <source>J Infect Dis</source>
<volume>194</volume>:
<fpage>1098</fpage>&#x02013;<lpage>1107</lpage>.<pub-id pub-id-type="pmid">16991084</pub-id></mixed-citation></ref><ref id="pone.0043803-Nasi1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Nasi</surname><given-names>M</given-names></name>, <name><surname>Pinti</surname><given-names>M</given-names></name>, <name><surname>Bugarini</surname><given-names>R</given-names></name>, <name><surname>Troiano</surname><given-names>L</given-names></name>, <name><surname>Lugli</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Genetic
polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in
CD4+ T cell count after antiretroviral therapy in drug-naive
HIV-positive patients</article-title>. <source>Immunogenetics</source>
<volume>57</volume>:
<fpage>628</fpage>&#x02013;<lpage>635</lpage>.<pub-id pub-id-type="pmid">16158329</pub-id></mixed-citation></ref><ref id="pone.0043803-Varbanov1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Varbanov</surname><given-names>M</given-names></name>, <name><surname>Espert</surname><given-names>L</given-names></name>, <name><surname>Biard-Piechaczyk</surname><given-names>M</given-names></name> (<year>2006</year>) <article-title>Mechanisms of CD4 T-cell depletion
triggered by HIV-1 viral proteins</article-title>. <source>AIDS Rev</source>
<volume>8</volume>:
<fpage>221</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">17219737</pub-id></mixed-citation></ref><ref id="pone.0043803-Petit1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Petit</surname><given-names>F</given-names></name>, <name><surname>Arnoult</surname><given-names>D</given-names></name>, <name><surname>Viollet</surname><given-names>L</given-names></name>, <name><surname>Estaquier</surname><given-names>J</given-names></name> (<year>2003</year>) <article-title>Intrinsic and extrinsic pathways
signaling during HIV-1 mediated cell death</article-title>.
<source>Biochimie</source>
<volume>85</volume>:
<fpage>795</fpage>&#x02013;<lpage>811</lpage>.<pub-id pub-id-type="pmid">14585547</pub-id></mixed-citation></ref><ref id="pone.0043803-Hunt1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Hunt</surname><given-names>PW</given-names></name>, <name><surname>Martin</surname><given-names>JN</given-names></name>, <name><surname>Sinclair</surname><given-names>E</given-names></name>, <name><surname>Bredt</surname><given-names>B</given-names></name>, <name><surname>Hagos</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>T cell
activation is associated with lower CD4+ T cell gains in human
immunodeficiency virus-infected patients with sustained viral suppression
during antiretroviral therapy</article-title>. <source>J Infect Dis</source>
<volume>187</volume>:
<fpage>1534</fpage>&#x02013;<lpage>1543</lpage>.<pub-id pub-id-type="pmid">12721933</pub-id></mixed-citation></ref><ref id="pone.0043803-Deeks1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Deeks</surname><given-names>SG</given-names></name>, <name><surname>Kitchen</surname><given-names>CM</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>Guo</surname><given-names>H</given-names></name>, <name><surname>Gascon</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Immune
activation set point during early HIV infection predicts subsequent
CD4+ T-cell changes independent of viral load</article-title>.
<source>Blood</source>
<volume>104</volume>:
<fpage>942</fpage>&#x02013;<lpage>947</lpage>.<pub-id pub-id-type="pmid">15117761</pub-id></mixed-citation></ref><ref id="pone.0043803-Goicoechea1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Goicoechea</surname><given-names>M</given-names></name>, <name><surname>Smith</surname><given-names>DM</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>May</surname><given-names>S</given-names></name>, <name><surname>Tenorio</surname><given-names>AR</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Determinants of
CD4+ T cell recovery during suppressive antiretroviral therapy:
association of immune activation, T cell maturation markers, and cellular
HIV-1 DNA</article-title>. <source>J Infect Dis</source>
<volume>194</volume>:
<fpage>29</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">16741879</pub-id></mixed-citation></ref><ref id="pone.0043803-Massanella1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Massanella</surname><given-names>M</given-names></name>, <name><surname>Negredo</surname><given-names>E</given-names></name>, <name><surname>Perez-Alvarez</surname><given-names>N</given-names></name>, <name><surname>Puig</surname><given-names>J</given-names></name>, <name><surname>Ruiz-Hernandez</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>CD4 T-cell
hyperactivation and susceptibility to cell death determine poor CD4 T-cell
recovery during suppressive HAART</article-title>. <source>AIDS</source>
<volume>24</volume>:
<fpage>959</fpage>&#x02013;<lpage>968</lpage>.<pub-id pub-id-type="pmid">20177358</pub-id></mixed-citation></ref><ref id="pone.0043803-Gandhi1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Gandhi</surname><given-names>RT</given-names></name>, <name><surname>Spritzler</surname><given-names>J</given-names></name>, <name><surname>Chan</surname><given-names>E</given-names></name>, <name><surname>Asmuth</surname><given-names>DM</given-names></name>, <name><surname>Rodriguez</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Effect of
baseline- and treatment-related factors on immunologic recovery after
initiation of antiretroviral therapy in HIV-1-positive subjects: results
from ACTG 384</article-title>. <source>J Acquir Immune Defic Syndr</source>
<volume>42</volume>:
<fpage>426</fpage>&#x02013;<lpage>434</lpage>.<pub-id pub-id-type="pmid">16810109</pub-id></mixed-citation></ref><ref id="pone.0043803-Gougeon1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Gougeon</surname><given-names>ML</given-names></name>, <name><surname>Lecoeur</surname><given-names>H</given-names></name>, <name><surname>Dulioust</surname><given-names>A</given-names></name>, <name><surname>Enouf</surname><given-names>MG</given-names></name>, <name><surname>Crouvoiser</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>Programmed cell
death in peripheral lymphocytes from HIV-infected persons: increased
susceptibility to apoptosis of CD4 and CD8 T cells correlates with
lymphocyte activation and with disease progression</article-title>.
<source>J Immunol</source>
<volume>156</volume>:
<fpage>3509</fpage>&#x02013;<lpage>3520</lpage>.<pub-id pub-id-type="pmid">8617980</pub-id></mixed-citation></ref><ref id="pone.0043803-Groux1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Groux</surname><given-names>H</given-names></name>, <name><surname>Torpier</surname><given-names>G</given-names></name>, <name><surname>Monte</surname><given-names>D</given-names></name>, <name><surname>Mouton</surname><given-names>Y</given-names></name>, <name><surname>Capron</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>1992</year>)
<article-title>Activation-induced death by apoptosis in CD4+ T cells
from human immunodeficiency virus-infected asymptomatic
individuals</article-title>. <source>J Exp Med</source>
<volume>175</volume>:
<fpage>331</fpage>&#x02013;<lpage>340</lpage>.<pub-id pub-id-type="pmid">1346269</pub-id></mixed-citation></ref><ref id="pone.0043803-Gougeon2"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Gougeon</surname><given-names>ML</given-names></name>, <name><surname>Piacentini</surname><given-names>M</given-names></name> (<year>2009</year>) <article-title>New insights on the role of apoptosis
and autophagy in HIV pathogenesis</article-title>.
<source>Apoptosis</source>
<volume>14</volume>:
<fpage>501</fpage>&#x02013;<lpage>508</lpage>.<pub-id pub-id-type="pmid">19199038</pub-id></mixed-citation></ref><ref id="pone.0043803-Nakanjako1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Nakanjako</surname><given-names>D</given-names></name>, <name><surname>Ssewanyana</surname><given-names>I</given-names></name>, <name><surname>Mayanja-Kizza</surname><given-names>H</given-names></name>, <name><surname>Kiragga</surname><given-names>A</given-names></name>, <name><surname>Colebunders</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>High T-cell
immune activation and immune exhaustion among individuals with suboptimal
CD4 recovery after 4 years of antiretroviral therapy in an African
cohort</article-title>. <source>BMC Infect Dis</source>
<volume>11</volume>: <fpage>43</fpage>.<pub-id pub-id-type="pmid">21299909</pub-id></mixed-citation></ref><ref id="pone.0043803-Robbins1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Robbins</surname><given-names>GK</given-names></name>, <name><surname>Spritzler</surname><given-names>JG</given-names></name>, <name><surname>Chan</surname><given-names>ES</given-names></name>, <name><surname>Asmuth</surname><given-names>DM</given-names></name>, <name><surname>Gandhi</surname><given-names>RT</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Incomplete
reconstitution of T cell subsets on combination antiretroviral therapy in
the AIDS Clinical Trials Group protocol 384</article-title>. <source>Clin
Infect Dis</source>
<volume>48</volume>:
<fpage>350</fpage>&#x02013;<lpage>361</lpage>.<pub-id pub-id-type="pmid">19123865</pub-id></mixed-citation></ref><ref id="pone.0043803-Bouillet1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Bouillet</surname><given-names>P</given-names></name>, <name><surname>O&#x02019;Reilly</surname><given-names>LA</given-names></name> (<year>2009</year>) <article-title>CD95, BIM and T cell
homeostasis</article-title>. <source>Nat Rev Immunol</source>
<volume>9</volume>:
<fpage>514</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">19543226</pub-id></mixed-citation></ref><ref id="pone.0043803-Grimaldi1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Grimaldi</surname><given-names>M</given-names></name>, <name><surname>Denizot</surname><given-names>M</given-names></name>, <name><surname>Espert</surname><given-names>L</given-names></name>, <name><surname>Robert-Hebmann</surname><given-names>V</given-names></name>, <name><surname>Biard-Piechaczyk</surname><given-names>M</given-names></name> (<year>2005</year>) <article-title>Mitochondria-dependent apoptosis in
T-cell homeostasis</article-title>. <source>Curr Opin Investig
Drugs</source>
<volume>6</volume>:
<fpage>1095</fpage>&#x02013;<lpage>1102</lpage>.</mixed-citation></ref><ref id="pone.0043803-Negredo1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Negredo</surname><given-names>E</given-names></name>, <name><surname>Massanella</surname><given-names>M</given-names></name>, <name><surname>Puig</surname><given-names>J</given-names></name>, <name><surname>Perez-Alvarez</surname><given-names>N</given-names></name>, <name><surname>Gallego-Escuredo</surname><given-names>JM</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Nadir CD4 T cell
count as predictor and high CD4 T cell intrinsic apoptosis as final
mechanism of poor CD4 T cell recovery in virologically suppressed
HIV-infected patients: clinical implications</article-title>. <source>Clin
Infect Dis</source>
<volume>50</volume>:
<fpage>1300</fpage>&#x02013;<lpage>1308</lpage>.<pub-id pub-id-type="pmid">20367229</pub-id></mixed-citation></ref><ref id="pone.0043803-Badley1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Badley</surname><given-names>AD</given-names></name>, <name><surname>Roumier</surname><given-names>T</given-names></name>, <name><surname>Lum</surname><given-names>JJ</given-names></name>, <name><surname>Kroemer</surname><given-names>G</given-names></name> (<year>2003</year>) <article-title>Mitochondrion-mediated apoptosis in
HIV-1 infection</article-title>. <source>Trends Pharmacol Sci</source>
<volume>24</volume>:
<fpage>298</fpage>&#x02013;<lpage>305</lpage>.<pub-id pub-id-type="pmid">12823956</pub-id></mixed-citation></ref><ref id="pone.0043803-Chavan1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Chavan</surname><given-names>SJ</given-names></name>, <name><surname>Tamma</surname><given-names>SL</given-names></name>, <name><surname>Kaplan</surname><given-names>M</given-names></name>, <name><surname>Gersten</surname><given-names>M</given-names></name>, <name><surname>Pahwa</surname><given-names>SG</given-names></name> (<year>1999</year>) <article-title>Reduction in T cell apoptosis in
patients with HIV disease following antiretroviral therapy</article-title>.
<source>Clin Immunol</source>
<volume>93</volume>: <fpage>24</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">10497008</pub-id></mixed-citation></ref><ref id="pone.0043803-Johnson1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Johnson</surname><given-names>N</given-names></name>, <name><surname>Parkin</surname><given-names>JM</given-names></name> (<year>1998</year>) <article-title>Anti-retroviral therapy reverses
HIV-associated abnormalities in lymphocyte apoptosis</article-title>.
<source>Clin Exp Immunol</source>
<volume>113</volume>:
<fpage>229</fpage>&#x02013;<lpage>234</lpage>.<pub-id pub-id-type="pmid">9717972</pub-id></mixed-citation></ref><ref id="pone.0043803-Wallace1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Wallace</surname><given-names>DC</given-names></name>, <name><surname>Brown</surname><given-names>MD</given-names></name>, <name><surname>Lott</surname><given-names>MT</given-names></name> (<year>1999</year>) <article-title>Mitochondrial DNA variation in human
evolution and disease</article-title>. <source>Gene</source>
<volume>238</volume>:
<fpage>211</fpage>&#x02013;<lpage>230</lpage>.<pub-id pub-id-type="pmid">10570998</pub-id></mixed-citation></ref><ref id="pone.0043803-GomezDuran1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Gomez-Duran</surname><given-names>A</given-names></name>, <name><surname>Pacheu-Grau</surname><given-names>D</given-names></name>, <name><surname>Lopez-Gallardo</surname><given-names>E</given-names></name>, <name><surname>Diez-Sanchez</surname><given-names>C</given-names></name>, <name><surname>Montoya</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Unmasking the
causes of multifactorial disorders: OXPHOS differences between mitochondrial
haplogroups</article-title>. <source>Hum Mol Genet</source>
<volume>19</volume>:
<fpage>3343</fpage>&#x02013;<lpage>3353</lpage>.<pub-id pub-id-type="pmid">20566709</pub-id></mixed-citation></ref><ref id="pone.0043803-Brown1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Brown</surname><given-names>MD</given-names></name>, <name><surname>Trounce</surname><given-names>IA</given-names></name>, <name><surname>Jun</surname><given-names>AS</given-names></name>, <name><surname>Allen</surname><given-names>JC</given-names></name>, <name><surname>Wallace</surname><given-names>DC</given-names></name> (<year>2000</year>) <article-title>Functional analysis of lymphoblast
and cybrid mitochondria containing the 3460, 11778, or 14484 Leber&#x02019;s
hereditary optic neuropathy mitochondrial DNA mutation</article-title>.
<source>J Biol Chem</source>
<volume>275</volume>:
<fpage>39831</fpage>&#x02013;<lpage>39836</lpage>.<pub-id pub-id-type="pmid">10976107</pub-id></mixed-citation></ref><ref id="pone.0043803-DeBenedictis1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>De Benedictis</surname><given-names>G</given-names></name>, <name><surname>Rose</surname><given-names>G</given-names></name>, <name><surname>Carrieri</surname><given-names>G</given-names></name>, <name><surname>De Luca</surname><given-names>M</given-names></name>, <name><surname>Falcone</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Mitochondrial
DNA inherited variants are associated with successful aging and longevity in
humans</article-title>. <source>FASEB J</source>
<volume>13</volume>: <fpage>1532</fpage>.<pub-id pub-id-type="pmid">10463944</pub-id></mixed-citation></ref><ref id="pone.0043803-Mancuso1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Mancuso</surname><given-names>M</given-names></name>, <name><surname>Filosto</surname><given-names>M</given-names></name>, <name><surname>Orsucci</surname><given-names>D</given-names></name>, <name><surname>Siciliano</surname><given-names>G</given-names></name> (<year>2008</year>) <article-title>Mitochondrial DNA sequence variation
and neurodegeneration</article-title>. <source>Hum Genomics</source>
<volume>3</volume>: <fpage>71</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">19129091</pub-id></mixed-citation></ref><ref id="pone.0043803-Nishigaki1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Nishigaki</surname><given-names>Y</given-names></name>, <name><surname>Fuku</surname><given-names>N</given-names></name>, <name><surname>Tanaka</surname><given-names>M</given-names></name> (<year>2010</year>) <article-title>Mitochondrial haplogroups associated
with lifestyle-related diseases and longevity in the Japanese
population</article-title>. <source>Geriatr Gerontol Int</source>
<volume>10</volume>
<issue>Suppl 1</issue>:
<fpage>S221</fpage>&#x02013;<lpage>235</lpage>.<pub-id pub-id-type="pmid">20590837</pub-id></mixed-citation></ref><ref id="pone.0043803-Raule1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Raule</surname><given-names>N</given-names></name>, <name><surname>Sevini</surname><given-names>F</given-names></name>, <name><surname>Santoro</surname><given-names>A</given-names></name>, <name><surname>Altilia</surname><given-names>S</given-names></name>, <name><surname>Franceschi</surname><given-names>C</given-names></name> (<year>2007</year>) <article-title>Association studies on human
mitochondrial DNA: methodological aspects and results in the most common
age-related diseases</article-title>. <source>Mitochondrion</source>
<volume>7</volume>: <fpage>29</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">17306632</pub-id></mixed-citation></ref><ref id="pone.0043803-Casula1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Casula</surname><given-names>M</given-names></name>, <name><surname>Vrisekoop</surname><given-names>N</given-names></name>, <name><surname>Wit</surname><given-names>FW</given-names></name>, <name><surname>de Baar</surname><given-names>MP</given-names></name>, <name><surname>de Ronde</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Mitochondrial
DNA decline in T cells of HIV-1 seroconverters may be dependent on immune
activation</article-title>. <source>J Infect Dis</source>
<volume>196</volume>:
<fpage>371</fpage>&#x02013;<lpage>376</lpage>.<pub-id pub-id-type="pmid">17597451</pub-id></mixed-citation></ref><ref id="pone.0043803-Maagaard1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Maagaard</surname><given-names>A</given-names></name>, <name><surname>Holberg-Petersen</surname><given-names>M</given-names></name>, <name><surname>Kvittingen</surname><given-names>EA</given-names></name>, <name><surname>Sandvik</surname><given-names>L</given-names></name>, <name><surname>Bruun</surname><given-names>JN</given-names></name> (<year>2006</year>) <article-title>Depletion of mitochondrial DNA
copies/cell in peripheral blood mononuclear cells in HIV-1-infected
treatment-naive patients</article-title>. <source>HIV Med</source>
<volume>7</volume>: <fpage>53</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">16313293</pub-id></mixed-citation></ref><ref id="pone.0043803-Hendrickson1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Hendrickson</surname><given-names>SL</given-names></name>, <name><surname>Hutcheson</surname><given-names>HB</given-names></name>, <name><surname>Ruiz-Pesini</surname><given-names>E</given-names></name>, <name><surname>Poole</surname><given-names>JC</given-names></name>, <name><surname>Lautenberger</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Mitochondrial
DNA haplogroups influence AIDS progression</article-title>.
<source>AIDS</source>
<volume>22</volume>:
<fpage>2429</fpage>&#x02013;<lpage>2439</lpage>.<pub-id pub-id-type="pmid">19005266</pub-id></mixed-citation></ref><ref id="pone.0043803-Grady1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Grady</surname><given-names>BJ</given-names></name>, <name><surname>Samuels</surname><given-names>DC</given-names></name>, <name><surname>Robbins</surname><given-names>GK</given-names></name>, <name><surname>Selph</surname><given-names>D</given-names></name>, <name><surname>Canter</surname><given-names>JA</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Mitochondrial
Genomics and CD4 T-Cell Count Recovery After Antiretroviral Therapy
Initiation in AIDS Clinical Trials Group Study 384</article-title>.
<source>J Acquir Immune Defic Syndr</source>
<volume>58</volume>:
<fpage>363</fpage>&#x02013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">21792066</pub-id></mixed-citation></ref><ref id="pone.0043803-Robbins2"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Robbins</surname><given-names>GK</given-names></name>, <name><surname>De Gruttola</surname><given-names>V</given-names></name>, <name><surname>Shafer</surname><given-names>RW</given-names></name>, <name><surname>Smeaton</surname><given-names>LM</given-names></name>, <name><surname>Snyder</surname><given-names>SW</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Comparison of
sequential three-drug regimens as initial therapy for HIV-1
infection</article-title>. <source>N Engl J Med</source>
<volume>349</volume>:
<fpage>2293</fpage>&#x02013;<lpage>2303</lpage>.<pub-id pub-id-type="pmid">14668455</pub-id></mixed-citation></ref><ref id="pone.0043803-Shafer1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Shafer</surname><given-names>RW</given-names></name>, <name><surname>Smeaton</surname><given-names>LM</given-names></name>, <name><surname>Robbins</surname><given-names>GK</given-names></name>, <name><surname>De Gruttola</surname><given-names>V</given-names></name>, <name><surname>Snyder</surname><given-names>SW</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Comparison of
four-drug regimens and pairs of sequential three-drug regimens as initial
therapy for HIV-1 infection</article-title>. <source>N Engl J Med</source>
<volume>349</volume>:
<fpage>2304</fpage>&#x02013;<lpage>2315</lpage>.<pub-id pub-id-type="pmid">14668456</pub-id></mixed-citation></ref><ref id="pone.0043803-Haas2"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Haas</surname><given-names>DW</given-names></name>, <name><surname>Wilkinson</surname><given-names>GR</given-names></name>, <name><surname>Kuritzkes</surname><given-names>DR</given-names></name>, <name><surname>Richman</surname><given-names>DD</given-names></name>, <name><surname>Nicotera</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>A
multi-investigator/institutional DNA bank for AIDS-related human genetic
studies: AACTG Protocol A5128</article-title>. <source>HIV Clin
Trials</source>
<volume>4</volume>:
<fpage>287</fpage>&#x02013;<lpage>300</lpage>.<pub-id pub-id-type="pmid">14583845</pub-id></mixed-citation></ref><ref id="pone.0043803-Hulgan1"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Hulgan</surname><given-names>T</given-names></name>, <name><surname>Haas</surname><given-names>DW</given-names></name>, <name><surname>Haines</surname><given-names>JL</given-names></name>, <name><surname>Ritchie</surname><given-names>MD</given-names></name>, <name><surname>Robbins</surname><given-names>GK</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Mitochondrial
haplogroups and peripheral neuropathy during antiretroviral therapy: an
adult AIDS clinical trials group study</article-title>.
<source>Aids</source>
<volume>19</volume>:
<fpage>1341</fpage>&#x02013;<lpage>1349</lpage>.<pub-id pub-id-type="pmid">16103764</pub-id></mixed-citation></ref><ref id="pone.0043803-Kallianpur1"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Kallianpur</surname><given-names>AR</given-names></name>, <name><surname>Hulgan</surname><given-names>T</given-names></name>, <name><surname>Canter</surname><given-names>JA</given-names></name>, <name><surname>Ritchie</surname><given-names>MD</given-names></name>, <name><surname>Haines</surname><given-names>JL</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Hemochromatosis
(HFE) gene mutations and peripheral neuropathy during antiretroviral
therapy</article-title>. <source>Aids</source>
<volume>20</volume>:
<fpage>1503</fpage>&#x02013;<lpage>1513</lpage>.<pub-id pub-id-type="pmid">16847405</pub-id></mixed-citation></ref><ref id="pone.0043803-Motsinger1"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Motsinger</surname><given-names>AA</given-names></name>, <name><surname>Ritchie</surname><given-names>MD</given-names></name>, <name><surname>Shafer</surname><given-names>RW</given-names></name>, <name><surname>Robbins</surname><given-names>GK</given-names></name>, <name><surname>Morse</surname><given-names>GD</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Multilocus
genetic interactions and response to efavirenz-containing regimens: an adult
AIDS clinical trials group study</article-title>. <source>Pharmacogenet
Genomics</source>
<volume>16</volume>:
<fpage>837</fpage>&#x02013;<lpage>845</lpage>.<pub-id pub-id-type="pmid">17047492</pub-id></mixed-citation></ref><ref id="pone.0043803-Maitra1"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Maitra</surname><given-names>A</given-names></name>, <name><surname>Cohen</surname><given-names>Y</given-names></name>, <name><surname>Gillespie</surname><given-names>SE</given-names></name>, <name><surname>Mambo</surname><given-names>E</given-names></name>, <name><surname>Fukushima</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>The Human
MitoChip: a high-throughput sequencing microarray for mitochondrial mutation
detection</article-title>. <source>Genome Res</source>
<volume>14</volume>:
<fpage>812</fpage>&#x02013;<lpage>819</lpage>.<pub-id pub-id-type="pmid">15123581</pub-id></mixed-citation></ref><ref id="pone.0043803-Andrews1"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Andrews</surname><given-names>RM</given-names></name>, <name><surname>Kubacka</surname><given-names>I</given-names></name>, <name><surname>Chinnery</surname><given-names>PF</given-names></name>, <name><surname>Lightowlers</surname><given-names>RN</given-names></name>, <name><surname>Turnbull</surname><given-names>DM</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Reanalysis and
revision of the Cambridge reference sequence for human mitochondrial
DNA</article-title>. <source>Nat Genet</source>
<volume>23</volume>: <fpage>147</fpage>.<pub-id pub-id-type="pmid">10508508</pub-id></mixed-citation></ref><ref id="pone.0043803-Herrnstadt1"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Herrnstadt</surname><given-names>C</given-names></name>, <name><surname>Elson</surname><given-names>JL</given-names></name>, <name><surname>Fahy</surname><given-names>E</given-names></name>, <name><surname>Preston</surname><given-names>G</given-names></name>, <name><surname>Turnbull</surname><given-names>DM</given-names></name>, <etal>et al</etal> (<year>2002</year>)
<article-title>Reduced-median-network analysis of complete mitochondrial DNA
coding-region sequences for the major African, Asian, and European
haplogroups</article-title>. <source>Am J Hum Genet</source>
<volume>70</volume>:
<fpage>1152</fpage>&#x02013;<lpage>1171</lpage>.<pub-id pub-id-type="pmid">11938495</pub-id></mixed-citation></ref><ref id="pone.0043803-Garg1"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Garg</surname><given-names>H</given-names></name>, <name><surname>Blumenthal</surname><given-names>R</given-names></name> (<year>2006</year>) <article-title>HIV gp41-induced apoptosis is
mediated by caspase-3-dependent mitochondrial depolarization, which is
inhibited by HIV protease inhibitor nelfinavir</article-title>. <source>J
Leukoc Biol</source>
<volume>79</volume>:
<fpage>351</fpage>&#x02013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">16330530</pub-id></mixed-citation></ref><ref id="pone.0043803-Peraire1"><label>50</label><mixed-citation publication-type="journal">
<name><surname>Peraire</surname><given-names>J</given-names></name>, <name><surname>Miro</surname><given-names>O</given-names></name>, <name><surname>Saumoy</surname><given-names>M</given-names></name>, <name><surname>Domingo</surname><given-names>P</given-names></name>, <name><surname>Pedrol</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>HIV-1-infected
long-term non-progressors have milder mitochondrial impairment and lower
mitochondrially-driven apoptosis in peripheral blood mononuclear cells than
typical progressors</article-title>. <source>Curr HIV Res</source>
<volume>5</volume>:
<fpage>467</fpage>&#x02013;<lpage>473</lpage>.<pub-id pub-id-type="pmid">17896966</pub-id></mixed-citation></ref><ref id="pone.0043803-Miura1"><label>51</label><mixed-citation publication-type="journal">
<name><surname>Miura</surname><given-names>T</given-names></name>, <name><surname>Goto</surname><given-names>M</given-names></name>, <name><surname>Hosoya</surname><given-names>N</given-names></name>, <name><surname>Odawara</surname><given-names>T</given-names></name>, <name><surname>Kitamura</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Depletion of
mitochondrial DNA in HIV-1-infected patients and its amelioration by
antiretroviral therapy</article-title>. <source>J Med Virol</source>
<volume>70</volume>:
<fpage>497</fpage>&#x02013;<lpage>505</lpage>.<pub-id pub-id-type="pmid">12794710</pub-id></mixed-citation></ref><ref id="pone.0043803-Sternfeld1"><label>52</label><mixed-citation publication-type="journal">
<name><surname>Sternfeld</surname><given-names>T</given-names></name>, <name><surname>Schmid</surname><given-names>M</given-names></name>, <name><surname>Tischleder</surname><given-names>A</given-names></name>, <name><surname>Mudra</surname><given-names>S</given-names></name>, <name><surname>Schlamp</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>The influence of
HIV infection and antiretroviral therapy on the mitochondrial membrane
potential of peripheral mononuclear cells</article-title>. <source>Antivir
Ther</source>
<volume>12</volume>:
<fpage>769</fpage>&#x02013;<lpage>778</lpage>.<pub-id pub-id-type="pmid">17713160</pub-id></mixed-citation></ref><ref id="pone.0043803-Sternfeld2"><label>53</label><mixed-citation publication-type="journal">
<name><surname>Sternfeld</surname><given-names>T</given-names></name>, <name><surname>Tischleder</surname><given-names>A</given-names></name>, <name><surname>Schuster</surname><given-names>M</given-names></name>, <name><surname>Bogner</surname><given-names>JR</given-names></name> (<year>2009</year>) <article-title>Mitochondrial membrane potential and
apoptosis of blood mononuclear cells in untreated HIV-1 infected
patients</article-title>. <source>HIV Med</source>
<volume>10</volume>:
<fpage>512</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">19496834</pub-id></mixed-citation></ref><ref id="pone.0043803-Karamchand1"><label>54</label><mixed-citation publication-type="journal">
<name><surname>Karamchand</surname><given-names>L</given-names></name>, <name><surname>Dawood</surname><given-names>H</given-names></name>, <name><surname>Chuturgoon</surname><given-names>AA</given-names></name> (<year>2008</year>) <article-title>Lymphocyte mitochondrial
depolarization and apoptosis in HIV-1-infected HAART
patients</article-title>. <source>J Acquir Immune Defic Syndr</source>
<volume>48</volume>:
<fpage>381</fpage>&#x02013;<lpage>388</lpage>.<pub-id pub-id-type="pmid">18614930</pub-id></mixed-citation></ref><ref id="pone.0043803-Quintana1"><label>55</label><mixed-citation publication-type="journal">
<name><surname>Quintana</surname><given-names>A</given-names></name>, <name><surname>Pasche</surname><given-names>M</given-names></name>, <name><surname>Junker</surname><given-names>C</given-names></name>, <name><surname>Al-Ansary</surname><given-names>D</given-names></name>, <name><surname>Rieger</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Calcium
microdomains at the immunological synapse: how ORAI channels, mitochondria
and calcium pumps generate local calcium signals for efficient T-cell
activation</article-title>. <source>EMBO J</source>
<volume>30</volume>:
<fpage>3895</fpage>&#x02013;<lpage>3912</lpage>.<pub-id pub-id-type="pmid">21847095</pub-id></mixed-citation></ref><ref id="pone.0043803-Quintana2"><label>56</label><mixed-citation publication-type="journal">
<name><surname>Quintana</surname><given-names>A</given-names></name>, <name><surname>Schwindling</surname><given-names>C</given-names></name>, <name><surname>Wenning</surname><given-names>AS</given-names></name>, <name><surname>Becherer</surname><given-names>U</given-names></name>, <name><surname>Rettig</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>T cell
activation requires mitochondrial translocation to the immunological
synapse</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>104</volume>:
<fpage>14418</fpage>&#x02013;<lpage>14423</lpage>.<pub-id pub-id-type="pmid">17726106</pub-id></mixed-citation></ref><ref id="pone.0043803-Wang1"><label>57</label><mixed-citation publication-type="journal">
<name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Silva</surname><given-names>JP</given-names></name>, <name><surname>Gustafsson</surname><given-names>CM</given-names></name>, <name><surname>Rustin</surname><given-names>P</given-names></name>, <name><surname>Larsson</surname><given-names>NG</given-names></name> (<year>2001</year>) <article-title>Increased in vivo apoptosis in cells
lacking mitochondrial DNA gene expression</article-title>. <source>Proc Natl
Acad Sci U S A</source>
<volume>98</volume>:
<fpage>4038</fpage>&#x02013;<lpage>4043</lpage>.<pub-id pub-id-type="pmid">11259653</pub-id></mixed-citation></ref><ref id="pone.0043803-Mirabella1"><label>58</label><mixed-citation publication-type="journal">
<name><surname>Mirabella</surname><given-names>M</given-names></name>, <name><surname>Di Giovanni</surname><given-names>S</given-names></name>, <name><surname>Silvestri</surname><given-names>G</given-names></name>, <name><surname>Tonali</surname><given-names>P</given-names></name>, <name><surname>Servidei</surname><given-names>S</given-names></name> (<year>2000</year>) <article-title>Apoptosis in mitochondrial
encephalomyopathies with mitochondrial DNA mutations: a potential pathogenic
mechanism</article-title>. <source>Brain 123 (Pt</source>
<volume>1)</volume>:
<fpage>93</fpage>&#x02013;<lpage>104</lpage>.</mixed-citation></ref><ref id="pone.0043803-Geromel1"><label>59</label><mixed-citation publication-type="journal">
<name><surname>Geromel</surname><given-names>V</given-names></name>, <name><surname>Kadhom</surname><given-names>N</given-names></name>, <name><surname>Cebalos-Picot</surname><given-names>I</given-names></name>, <name><surname>Ouari</surname><given-names>O</given-names></name>, <name><surname>Polidori</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2001</year>)
<article-title>Superoxide-induced massive apoptosis in cultured skin
fibroblasts harboring the neurogenic ataxia retinitis pigmentosa (NARP)
mutation in the ATPase-6 gene of the mitochondrial DNA</article-title>.
<source>Hum Mol Genet</source>
<volume>10</volume>:
<fpage>1221</fpage>&#x02013;<lpage>1228</lpage>.<pub-id pub-id-type="pmid">11371515</pub-id></mixed-citation></ref><ref id="pone.0043803-Nasi2"><label>60</label><mixed-citation publication-type="journal">
<name><surname>Nasi</surname><given-names>M</given-names></name>, <name><surname>Guaraldi</surname><given-names>G</given-names></name>, <name><surname>Orlando</surname><given-names>G</given-names></name>, <name><surname>Durante</surname><given-names>C</given-names></name>, <name><surname>Pinti</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Mitochondrial
DNA Haplogroups and Highly Active Antiretroviral Therapy-Related
Lipodystrophy</article-title>. <source>Clin Infect Dis</source>
<volume>47</volume>:
<fpage>962</fpage>&#x02013;<lpage>968</lpage>.<pub-id pub-id-type="pmid">18752438</pub-id></mixed-citation></ref><ref id="pone.0043803-Krishnan1"><label>61</label><mixed-citation publication-type="journal">
<name><surname>Krishnan</surname><given-names>S</given-names></name>, <name><surname>Schouten</surname><given-names>JT</given-names></name>, <name><surname>Jacobson</surname><given-names>DL</given-names></name>, <name><surname>Benson</surname><given-names>CA</given-names></name>, <name><surname>Collier</surname><given-names>AC</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Incidence of
non-AIDS-defining cancer in antiretroviral treatment-naive subjects after
antiretroviral treatment initiation: an ACTG longitudinal linked randomized
trials analysis</article-title>. <source>Oncology</source>
<volume>80</volume>: <fpage>42</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">21606663</pub-id></mixed-citation></ref></ref-list></back></article>